<SEC-DOCUMENT>0001104659-24-071307.txt : 20240613
<SEC-HEADER>0001104659-24-071307.hdr.sgml : 20240613
<ACCEPTANCE-DATETIME>20240613163854
ACCESSION NUMBER:		0001104659-24-071307
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20240613
DATE AS OF CHANGE:		20240613

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gain Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001819411
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				851726310
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-265061
		FILM NUMBER:		241041801

	BUSINESS ADDRESS:	
		STREET 1:		4800 HAMPDEN LANE
		STREET 2:		SUITE 200
		CITY:			BETHESDA
		STATE:			MD
		ZIP:			20814
		BUSINESS PHONE:		(301) 500-1556

	MAIL ADDRESS:	
		STREET 1:		4800 HAMPDEN LANE
		STREET 2:		SUITE 200
		CITY:			BETHESDA
		STATE:			MD
		ZIP:			20814
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tm2416858-1_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<html>
  <head>
    <title>tm2416858-1_424b5 - none - 5.8437794s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:595.31pt;">
    <div style="position:relative;overflow:hidden;min-height:775.71pt;page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="position:absolute;top:738.83pt;left:24pt;height:30.02pt;width:706pt;transform-origin:0pt -0pt;transform:rotate(-90deg) translate(0%, 0%);">
        <div style="text-align:justify; width:706pt; line-height:9.5pt;font-weight:bold;color:#FC0014;font-family:Helvetica, Arial, sans-serif;">
          <font style="letter-spacing:-0.08pt;">The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and has become effective. This preliminary prospectus supplement is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</font><font style="color:#000000;letter-spacing:-0.08pt;"> </font>
          <br >
        </div>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:63pt;width:505.31pt;">
        <div style="text-align:right; width:505.31pt; line-height:10pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#8202;&#8202;Filed Pursuant to Rule&#160;424(b)(5)</font>&#8203;</div>
        <div style="text-align:right; width:505.31pt; line-height:10pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#8202;&#8202;Registration No. 333-265061</font>&#8203;</div>
        <div style="margin-top:11.7pt; text-align:center; width:505.31pt; line-height:12pt;font-weight:bold;color:#FC0014;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">SUBJECT TO COMPLETION, DATED JUNE 13, 2024</font><font style="font-weight:normal;color:#000000;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:505.31pt; line-height:11.5pt;font-style:italic;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">PRELIMINARY PROSPECTUS SUPPLEMENT</font> <br ><font style="letter-spacing:-0.2pt;">(To Prospectus Dated June&#160;1, 2022)</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font></div>
        <div style="position:relative;margin-top:4pt; text-align:center; width:505.31pt;">
          <img src="lg_gaintherapeutics-4c.jpg" alt="[MISSING IMAGE: lg_gaintherapeutics-4c.jpg]" height="86" width="180" >
        </div>
        <div style="margin-top:7.9pt; text-align:center; width:505.31pt; line-height:14.5pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">&#8199;&#8199;&#8199;&#8199;SHARES OF COMMON STOCK</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:505.31pt; line-height:14pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">PRE-FUNDED WARRANTS TO PURCHASE UP TO &#8199;&#8199;&#8199;&#8199;SHARES OF </font>
          <br >
          <font style="letter-spacing:-0.28pt;">COMMON STOCK </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:505.31pt; line-height:14pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">UP TO &#8199;&#8199;&#8199;&#8199;&#8199; SHARES OF COMMON STOCK ISSUABLE UPON </font>
          <br >
          <font style="letter-spacing:-0.28pt;">EXERCISE OF THE PRE-FUNDED WARRANTS </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:505.31pt; line-height:14pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">UNDERWRITER WARRANTS TO PURCHASE UP TO &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; SHARES OF COMMON STOCK </font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:505.31pt; line-height:14pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">UP TO &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THE UNDERWRITER WARRANTS</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:505.31pt; line-height:8pt;">
          <font style="letter-spacing:0.16pt;">We are offering shares of our common stock, and, in lieu of shares of common stock to investors that so choose, pre-funded warrants to purchase shares of our common stock, or the &#8220;Pre-Funded Warrants&#8221;. The public offering price is $&#8199;&#8199;&#8199; per share. Each Pre-Funded Warrant will be exercisable immediately and is exercisable for one share of our common stock. The purchase price of each Pre-Funded Warrant is equal to the public offering price at which a share of common stock is sold to the public in this offering, minus $0.0001, and the exercise price of each Pre-Funded Warrant is $0.0001 per share of common stock. This prospectus supplement also relates to the offering of the shares of common stock issuable upon exercise of the Pre-Funded Warrants, or the &#8220;Pre-Funded Warrant Shares&#8221;. </font>
        </div>
        <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:8pt;">
          <font style="letter-spacing:0.16pt;">We are also registering the Underwriter Warrants (as defined below) and the shares of our common stock that are issuable from time to time upon exercise of the Underwriter Warrants. See &#8220;</font><font style="font-style:italic;letter-spacing:0.16pt;">Description of Securities We Are Offering</font><font style="letter-spacing:0.16pt;">&#8221; in this prospectus supplement for additional information. </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:505.31pt; line-height:8pt;">
          <font style="letter-spacing:0.16pt;">Our common stock is traded on the Nasdaq Global Market under the symbol &#8220;GANX&#8221;. The last reported sale price of our common stock on June 11, 2024 was $2.43 per share. There is no established public trading market for the Warrants (as defined below), and we do not expect a market to develop. Without an active trading market, the liquidity of the Warrants will be limited. In addition, we do not intend to apply for a listing of the Warrants on any national securities exchange or other nationally recognized trading system. </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:505.31pt; line-height:8pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">Investing in these securities involves a high degree of risk. Before buying our securities, you should carefully consider the risk factors described in &#8220;Risk Factors&#8221; beginning on page <a href="#tRIFA1">S-10</a> of this prospectus supplement and in the risks discussed under similar headings in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering.</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:505.31pt; line-height:8pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement is accurate or complete. Any representation to the contrary is a criminal offense.</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <table style="width:505.31pt;height:62.34pt;margin-top:4.5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:338.97pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">PER SHARE </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">PER</font>
                <br >
                <font style="letter-spacing:-0.16pt;">PRE-FUNDED</font>
                <br >
                <font style="letter-spacing:-0.16pt;">WARRANT</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">TOTAL </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:2.25pt 0pt 0.95pt 0pt; width:338.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.17pt;">Public offering price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.95pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.95pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.95pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.95pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; </td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.95pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.95pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:2.49pt 0pt 0.96pt 0pt; width:338.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.17pt;">Underwriting discounts and commissions</font><font style=" position:relative; bottom:3.5pt;font-size:5.5pt;letter-spacing:0.13pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.96pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.49pt 0pt 0.96pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.96pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.49pt 0pt 0.96pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.96pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.49pt 0pt 0.96pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.49999999999994pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8.5pt;">
            <td style="padding:2.49pt 0pt 0.96pt 0pt; width:338.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.17pt;">Proceeds to us, before expenses</font><font style=" position:relative; bottom:3.5pt;font-size:5.5pt;letter-spacing:0.13pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.96pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.49pt 0pt 0.96pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:8.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.96pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.49pt 0pt 0.96pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:12.085pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.49pt 0pt 0.96pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.49pt 0pt 0.96pt 0pt; min-width:25.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.75pt; width:505.31pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:5.3pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:8.5pt;">
          <font style="letter-spacing:0.17pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:9.5pt; text-align:left; margin-left:20pt;font-size:8.5pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.17pt;">Does not include the reimbursement of certain expenses of the underwriter we have agreed to pay. We have also agreed to issue the underwriter or its designees at the closing of this offering warrants to purchase the number of shares of common stock equal to 7% of the aggregate number of shares of common stock and Pre-Funded Warrants sold in this offering, including any shares of our common stock sold pursuant to the underwriter&#8217;s option to purchase additional shares of our common stock (the &#8220;Underwriter Warrants&#8221; and together with the Pre-Funded Warrants, the &#8220;Warrants&#8217;&#8217;). See the section entitled &#8220;Underwriting&#8221; beginning on page <a href="#tUND1">S-17</a> for a description of the compensation payable to the underwriter. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:9.5pt; margin-top:2.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:8.5pt;">
          <font style="letter-spacing:0.17pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:2.8pt; margin-bottom:0pt; line-height:9.5pt; text-align:left; margin-left:20pt;font-size:8.5pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.17pt;">The amount of the offering proceeds to us presented in this table does not give effect to the exercise, if any, of the Warrants being issued in connection with this offering.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:2pt; width:505.31pt; line-height:8pt;">
          <font style="letter-spacing:0.16pt;">We have granted the underwriter an option for a period of 30&#160;days from the date of this prospectus supplement to purchase up to an additional &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our common stock, at the price to the public set forth above, less underwriting discounts and commissions, to cover overallotments, if any. </font>
        </div>
        <div style="margin-left:20pt; margin-top:2pt; width:485.31pt; line-height:8.5pt;">
          <font style="letter-spacing:0.16pt;">The underwriter expects to deliver the securities against payment on or about &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, 2024. </font>
        </div>
        <div style="margin-top:2pt; text-align:center; width:505.31pt; line-height:8.5pt;font-style:italic;">
          <font style="letter-spacing:0.16pt;">Sole Bookrunner</font><font style="font-style:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:505.31pt; line-height:16.5pt;font-weight:bold;font-size:16pt;">
          <font style="letter-spacing:-0.32pt;">Titan Partners Group</font><font style="font-weight:normal;letter-spacing:0.32pt;"> </font>
        </div>
        <div style="margin-top:0.5pt; text-align:center; width:505.31pt; line-height:8.5pt;font-style:italic;">
          <font style="letter-spacing:0.16pt;">a division of American Capital Partners</font><font style="font-style:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:5pt; text-align:center; width:505.31pt; line-height:10.5pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">The date of this prospectus supplement is &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2024.</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a><a name="TOC2">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:151.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Prospectus Supplement</font>
        </div>
        <table style="width:456pt;height:188.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:422.72pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">PAGE </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATPS"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS SUPPLEMENT </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tATPS">S-1</a></font> <a href="#tATPS"></a></td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tFOST"><font style="letter-spacing:0.2pt;">FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tFOST">S-3</a></font> <a href="#tFOST"></a></td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPSS"><font style="letter-spacing:0.2pt;">PROSPECTUS SUPPLEMENT SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPSS">S-5</a></font> <a href="#tPSS"></a></td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA1"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA1">S-10</a></font> <a href="#tRIFA1"></a></td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP1"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP1">S-14</a></font> <a href="#tUOP1"></a></td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOSW"><font style="letter-spacing:0.2pt;">DESCRIPTION OF SECURITIES WE ARE OFFERING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOSW">S-15</a></font> <a href="#tDOSW"></a></td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDIL"><font style="letter-spacing:0.2pt;">DILUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDIL">S-16</a></font> <a href="#tDIL"></a></td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUND1"><font style="letter-spacing:0.2pt;">UNDERWRITING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUND1">S-17</a></font> <a href="#tUND1"></a></td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA1"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA1">S-25</a></font> <a href="#tLEMA1"></a></td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP1"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP1">S-25</a></font> <a href="#tEXP1"></a></td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF1"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF1">S-25</a></font> <a href="#tWYCF1"></a></td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:422.72pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIODB1"><font style="letter-spacing:0.2pt;">INCORPORATION OF DOCUMENTS BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIODB1">S-26</a></font>
            </td>
            <td style="padding:0pt;padding-left:1.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Prospectus</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:190pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATP"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tATP">i</a></font> <a href="#tATP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSUM"><font style="letter-spacing:0.2pt;">SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSUM">1</a></font> <a href="#tSUM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">7</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSNRF"><font style="letter-spacing:0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSNRF">8</a></font> <a href="#tSNRF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP">10</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOCS"><font style="letter-spacing:0.2pt;">DESCRIPTION OF CAPITAL STOCK </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOCS">11</a></font> <a href="#tDOCS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDODS"><font style="letter-spacing:0.2pt;">DESCRIPTION OF DEBT SECURITIES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDODS">15</a></font> <a href="#tDODS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLOOS"><font style="letter-spacing:0.2pt;">LEGAL OWNERSHIP OF SECURITIES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLOOS">24</a></font> <a href="#tLOOS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD"><font style="letter-spacing:0.2pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPOD">27</a></font> <a href="#tPOD"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">29</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP">29</a></font> <a href="#tEXP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF">30</a></font> <a href="#tWYCF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIOCI"><font style="letter-spacing:0.2pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIOCI">31</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tATPS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROSPECTUS SUPPLEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering of securities and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference in this prospectus supplement and the accompanying prospectus. The second part, the accompanying prospectus, provides more general information, some of which may not apply to this offering. Generally, when we refer to this prospectus supplement, we are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement and the information contained in the accompanying prospectus or any document incorporated by reference that was filed with the U.S. Securities and Exchange Commission, or SEC, before the date of this prospectus supplement, you should rely on the information in this prospectus supplement; provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date&#8201;-&#8201;for example, a document incorporated by reference in the accompanying prospectus&#8201;-&#8201;the statement in the document having the later date modifies or supersedes the earlier statement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Neither we nor the underwriter have authorized anyone to provide information different from that contained in this prospectus supplement and the accompanying prospectus, including any free writing prospectus that we have authorized for use in connection with this offering. When you make a decision about whether to invest in our securities, you should not rely upon any information other than the information in this prospectus supplement or the accompanying prospectus, including any free writing prospectus that we have authorized for use in connection with this offering. Neither the delivery of this prospectus supplement nor the accompanying prospectus, including any free writing prospectus that we have authorized for use in connection with this offering, nor the sale of our common stock means that information contained in this prospectus supplement and the accompanying prospectus, including any free writing prospectus that we have authorized for use in connection with this offering, is correct after their respective dates. It is important for you to read and consider all information contained in this prospectus supplement and the accompanying prospectus, including the information incorporated by reference into this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering in making your investment decision. You should also read and consider the information in the documents to which we have referred you in the sections entitled &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Documents by Reference&#8221; in this prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of our securities in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of our securities and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Unless otherwise indicated in this prospectus supplement or the context otherwise requires, all references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company,&#8221; and &#8220;Gain&#8221; refer to Gain Therapeutics, Inc. and its wholly owned subsidiaries. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Magellan&#8482; is our trademark. All other brand names and service marks, trademarks and other trade names appearing in this prospectus and the accompanying prospectus are the property of their respective </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:556pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">owners. This prospectus supplement and the accompanying prospectus may also include other trademarks, tradenames and service marks that are the property of their respective holders. Solely for convenience, trademarks and tradenames referred to in this prospectus supplement and the accompanying prospectus may appear without the </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> and &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable holder will not assert its rights, to these trademarks and tradenames.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tFOST">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our management&#8217;s judgment regarding future events. In many cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;intend,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other words of similar import, although some forward-looking statements are expressed differently. All statements other than statements of historical fact included in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein regarding our financial position, business strategy and plans or objectives for future operations are forward-looking statements. Without limiting the broader description of forward-looking statements above, we specifically note that statements regarding potential drug candidates, their potential therapeutic effect, the possibility of obtaining regulatory approval, our expected timing for completing clinical trials and clinical trial milestones for our drug candidates, our ability or the ability of our collaborators to manufacture and sell any products, market acceptance or our ability to earn a profit from sales or licenses of any drug candidate or to discover new drugs in the future are all forward-looking in nature. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to continue as a going concern and our needs for additional financing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to accurately estimate anticipated operating losses, expenses, future revenues and capital requirements, including our anticipated cash runway; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the success of our efforts, and those of our advisors, in exploring, and possibly executing on, our strategic alternatives, while preserving our cash balance to the extent practicable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and our research and development programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the success of our efforts to expand our pipeline of product candidates and develop marketable products through the use of our Magellan&#8482; platform; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to develop, obtain regulatory approval for and commercialize our current and future product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations regarding collaborations and other agreements with third parties and their potential benefits; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the timing of investigational new drug, or IND, submissions, initiation of preclinical studies and clinical trials, and timing of expected clinical results for our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our success in early preclinical studies, which may not be indicative of results obtained in later studies or clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the potential benefits of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to identify patients with the diseases treated by our product candidates, and to enroll healthy volunteers and patients in clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to obtain, maintain and protect our intellectual property; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our reliance upon intellectual property licensed from third parties, including the license to use certain components of the Magellan&#8482; platform; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to identify, recruit and retain key personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">developments or projections relating to our competitors or our industry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the impact of laws and regulations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations regarding government and third-party payor coverage and reimbursement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:168pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the impact of liquidity concerns at and failures of banks and other financial institutions, capital market instability, exchange rate fluctuations, supply chain disruptions and increases in commodity, energy and fuel prices; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the impacts of pandemics or endemics on our operations, access to capital, research and development and clinical trials and potential disruption in the operations and business of third-party manufacturers, contract research organizations, other service providers, and collaborators with whom we conduct business; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the impact of other global events, including political instability, natural disaster, events of terrorism and wars, including the war between Ukraine and Russia, and the corresponding tensions created from such conflict between Russia, the United States and countries in Europe as well as other countries such as China; and the conflict between Hamas and Israel; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">other factors and assumptions described in our Quarterly and Annual Reports. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should also consider carefully the statements set forth in the section titled &#8220;Risk Factors&#8221; in this prospectus supplement and in our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1819411/000155837024003943/ganx-20231231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2023</a> and our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1819411/000155837024008132/ganx-20240331x10q.htm">Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2024</a>, as updated by any other document that we subsequently file with the SEC and that is incorporated by reference into this prospectus supplement, which address various factors that could cause results or events to differ from those described in the forward-looking statements. All subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the applicable cautionary statements. We undertake no obligation to make any revisions to the forward-looking statements contained in this prospectus supplement or to update them to reflect events or circumstances occurring after the date hereof except as required by applicable law. Given these risks, uncertainties and other factors, many of which are beyond our control, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate, and you should not place undue reliance on these forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any forward-looking statements included herein speak only as of the date of this prospectus supplement, and we undertake no obligation to update any forward-looking information or statements for any reason after the date of this Prospectus Supplement to conform these statements to actual results or changes in expectations, except as required by law. All forward-looking statements attributable to us are expressly qualified by the foregoing cautionary statements.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPSS">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">PROSPECTUS SUPPLEMENT SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">This summary highlights information contained elsewhere or incorporated by reference in this prospectus supplement, the accompanying prospectus and in the documents we incorporate by reference. This summary does not contain all of the information that you should consider before deciding to invest in our common stock. You should read this entire prospectus supplement carefully, including the &#8220;Risk Factors&#8221; section contained in this prospectus supplement, the accompanying prospectus and in the documents we incorporate by reference.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (&#8220;CNS&#8221;) disorders, lysosomal storage disorders (&#8220;LSDs&#8221;), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">GT-02287&#8201;&#8212;&#8201;our lead product candidate for the treatment of GBA1 Parkinson&#8217;s disease and other synucleinopathies</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our clinical stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson&#8217;s disease. We have generated an extensive preclinical data package providing evidence of the mechanism of action and safety of GT-02287. In preclinical models of GBA1 Parkinson&#8217;s disease, GT-02287 has been shown to restore glucocerebrosidase, or GCase, function in the lysosome, reduce toxic lipid substrates and toxic forms of alpha-synuclein, improve survival of dopaminergic neurons, increase dopamine levels, completely restore locomotor function, and reduce plasma-based neurodegeneration maker, neurofilament light chain, or NfL, back to the level of healthy animals. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In September&#160;2023, we initiated in Australia the first-in-human Phase&#160;1 clinical trial to assess the safety, tolerability, pharmacokinetics, and food effect of GT-02287 in healthy participants. The study design includes a single ascending dose part during which the study participants receive one dose of GT-02287 at different dose levels, and a multiple ascending dose part during which the study participants receive one daily dose of GT-02287 for 14&#160;days at different dose levels. In February&#160;2024, we initiated the multiple ascending dose part of this Phase&#160;1 clinical trial, which we anticipate completing in the second quarter of 2024, with the availability of the quality assurance audited interim report in the third quarter of 2024. We are planning to expand the scope of this Phase&#160;1 clinical trial by amending the study protocol to include a cohort of 20&#8201;&#8211;&#8201;30 patients with Parkinson&#8217;s disease. These patients will be treated for a period of three&#160;months to evaluate safety, tolerability, and pharmacokinetics in patients, as well as to assess the effect of GT-02287 on certain biomarkers of the GCase disease cascade. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">In preparation for the treatment of Parkinson&#8217;s disease patients, in September&#160;2023, we initiated the sub chronic (13 weeks treatment) preclinical toxicity study. The in-vivo phase of the preclinical toxicity study was concluded in January&#160;2024 with the final, quality assurance audited, report expected by the beginning of the second quarter of 2024. In addition, we are planning to initiate the chronic (6&#160;months in rodents and 9&#160;months in non-rodents) preclinical toxicity study in the second half of 2024, enabling the conduct of clinical studies in patients with a GT-02287 treatment duration beyond three&#160;months. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Our Magellan&#8482; Platform</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We use our computational target and drug discovery platform, Magellan&#8482;, to discover novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. We believe that Magellan&#8482; is uniquely suited to identify allosteric binding sites on the protein surface, which are different from the active (or orthosteric) binding site where the natural ligand of the protein binds. Targeting an allosteric binding site instead of the active binding site of a protein provides numerous advantages, including: the ability to regulate proteins implicated in disease through several different mechanisms of action covering both functional and conformational effects, including stabilization, destabilization, targeted degradation, allosteric inhibition, and allosteric activation of the targeted protein; improved specificity of small molecules because binding to an allosteric binding site is non-competitive with the natural substrate that binds to the active binding site; and the ability to identify small molecules with more favorable drug-like properties. The </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Magellan&#8482; drug discovery platform is an evolution of its predecessor SEE-Tx</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, or Site-Directed Enzyme Enhancement Therapy. Magellan&#8482; integrates and adds to the foundational models of SEE-Tx</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> with proprietary AI and machine learning tools that enable the screening of over 50&#160;billion compounds. Discovering and targeting novel allosteric sites with our platform not only reduces traditional drug discovery timelines but enables rational drug design and offers the potential for superior small molecule drugs that are highly specific and that can penetrate hard to reach tissues and cross the blood-brain barrier. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Our Research Programs</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We have used the Magellan&#8482; drug discovery platform to identify novel allosteric sites and small molecules for all of our pipeline programs. We plan to continue to advance our existing research programs and initiate additional programs targeting allosteric binding sites identified with the Magellan&#8482; platform in various therapeutic areas through academic partnerships, co-development and licensing arrangements. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Pipeline of STARs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are leveraging our Magellan&#8482; technology platform to develop a pipeline of novel small molecule drug candidates to address complex diseases. The platform is disease agnostic and provides us with the ability to expand our pipeline, quickly, efficiently and at low cost. We are currently focusing on progressing our clinical-stage lead program in Parkinson&#8217;s disease. In addition, we plan to continue to advance our existing research programs and initiate additional programs targeting allosteric binding sites identified with the Magellan&#8482; platform in various therapeutic areas through discovery collaborations with industry partners and academic institutions. </font>
          </div>
          <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">Our Product Pipeline</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="position:relative;margin-top:9.1pt; text-align:center; width:456pt;">
            <img src="fc_pipeline-4clr.jpg" alt="[MISSING IMAGE: fc_pipeline-4clr.jpg]" height="271" width="578" >
          </div>
          <div style="margin-top:15.41pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Associated with Our Business</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our business is subject to numerous risks. You should read these risks before you invest in our securities. Specifically, our risks include, but are not limited to, the following: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.11pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.11pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">there is substantial doubt about our ability to continue as a going concern. We have a history of operating losses and expect to incur losses for the foreseeable future. We may never generate revenues or, if we are able to generate revenues, achieve profitability; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.82pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:3.82pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we have a limited operating history, and we expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">if preclinical studies or clinical trials for our product candidates cannot be initiated or completed or if they are delayed or unsuccessful, we will be unable to meet our future development and commercialization goals; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the disorders we seek to treat have low prevalence and it may be difficult to identify patients with these disorders, which may lead to delays in enrollment for our trials or slower commercial revenue if approved, and we may also face enrollment challenges as a result of other factors; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">our product candidates are novel and still in development. If we are unable to successfully develop, receive regulatory approval for and commercialize our current or future product candidates, our business will be harmed; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we have started testing one of our product candidates in clinical trials . Success in early preclinical studies or clinical trials may not be indicative of results obtained in later preclinical studies and clinical trials; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">clinical trials required for our product candidates are expensive and time-consuming, and their outcomes are uncertain; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we will need to raise additional capital, which may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates, and additional capital may not be available on favorable terms or at all, which may force us to delay, reduce the scope of or eliminate our research and development programs, reduce our commercialization efforts or curtail our operations; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we are subject to extensive and costly government regulation; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">even if we obtain regulatory approval to market our product candidates, our product candidates may not be accepted by the market; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we rely on a license to use the technology that is material to our business and if the agreement underlying the license were to be terminated or if other rights that may be necessary for commercializing our intended products cannot be obtained, it would halt our ability to market our products and technology, as well as have an immediate material adverse effect on our business, operating results and financial condition; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions, litigation, (including class actions) and mass arbitration demands, fines and penalties, disruptions of our business operations, reputational harm, loss of revenue or profits and other adverse business consequences; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">global and macroeconomic conditions, including worldwide economic, political and social instability could adversely affect our revenue, financial conditions, or results of operations. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Corporate Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We were incorporated under the laws of the state of Delaware (U.S.) on June&#160;26, 2020. Gain has been a publicly traded company since the Initial Public Offering (&#8220;IPO&#8221;) completed in March of 2021. Our shares of common stock trade on the Nasdaq Global Market under the ticker symbol &#8220;GANX.&#8221; </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our principal executive offices are located at 4800 Montgomery Lane, Suite 220, Bethesda, MD 20814. Our telephone number is (301) 500-1556. Our website address is http://www.gaintherapeutics.com. Information contained on or accessible through our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTHOF">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">THE OFFERING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:4pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Issuer</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Gain Therapeutics, Inc. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:4pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Common stock offered by us pursuant to this prospectus</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our common stock. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;font-size:9.8pt;">
              <font style="font-size:10pt;letter-spacing:-0.196pt;">Pre-Funded Warrants offered by us pursuant to this prospectus</font><font style="font-weight:normal;font-size:10pt;letter-spacing:0.196pt;"> </font> </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are also offering, in lieu of shares of common stock to certain investors that so choose, Pre-Funded Warrants to purchase shares of common stock. Each Pre-Funded Warrant will have an initial exercise price per share of $0.0001, subject to certain adjustments. The purchase price of each Pre-Funded Warrant is equal to the price at which a share of common stock is being sold to the public in this offering, minus $0.0001. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. For more information, see the section titled &#8220;Description of Securities We Are Offering &#8212; Pre-Funded Warrants.&#8221; This prospectus supplement also relates to the offering of the shares of common stock issuable upon the exercise of such Pre-Funded Warrants. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Underwriter Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Upon the closing of this offering, we have agreed to issue to the underwriter, or its designees, warrants (the &#8220;Underwriter Warrants&#8221;) to purchase a number of shares of common stock equal to an aggregate of 7% of the total number of shares and Pre-Funded Warrants sold in this public offering, including any shares of our common stock sold pursuant to the underwriter&#8217;s option to purchase additional shares of our common stock. The Underwriter Warrants will be exercisable at a per share exercise price equal to 125% of the offering price of the shares sold in this offering, or $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. The Underwriter Warrants are exercisable commencing six months after closing of this offering, and will be exercisable for a period of five years from the date of issuance. </font>
          </div>
          <div style="margin-left:168pt; margin-top:8pt; width:288pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">The Underwriter Warrants and the shares of common stock issuable upon the exercise thereof are being registered on the registration statement of which this prospectus supplement is a part. See &#8220;Underwriting &#8212; Underwriter Warrants&#8221; on page <a href="#UNWA">S-18</a> of this prospectus supplement. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Common stock to be outstanding after this offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our common stock (or&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares if the underwriter exercises its option to purchase additional shares in full) assuming all of the Pre-Funded Warrants issued in this offering are exercised and assuming no exercise of any Underwriter Warrants. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:4pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Option to purchase additional shares</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We have granted to the underwriter the option, exercisable for 30&#160;days from the date of this prospectus, to purchase up to &#8199;&#8199;&#8199;&#8199; additional shares of our common stock at the public offering price, less underwriting discounts and commissions, to cover overallotments, if any. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:4pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Use of proceeds</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We estimate that the net proceeds to us from this offering, excluding any proceeds that may be received upon the cash exercise of the Warrants, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, will be </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="margin-left:168pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million (or approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million if the underwriter exercises its option to purchase additional shares in full).</font>
          </div>
          <div style="margin-left:168pt; margin-top:4pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We intend to use the net proceeds of this offering to continue clinical and nonclinical development of our lead product candidate GT-02287 for the treatment of neurodegenerative diseases, including GBA1 Parkinson&#8217;s disease, and for general corporate purposes. See &#8220;Use of Proceeds&#8221; on page <a href="#tUOP1">S-14</a> of this prospectus supplement. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:4pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Risk factors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">See &#8220;Risk Factors&#8221; beginning on page <a href="#tRIFA1">S-10</a> of this prospectus supplement and in the documents included or incorporated into this prospectus for a discussion of certain factors you should carefully consider before deciding to invest in shares of our common stock. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:4pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">Lock-up Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our officers and directors have agreed with the underwriter, subject to certain exceptions, for a period of 60&#160;days from the closing of this offering, not to sell, transfer or otherwise dispose of, directly or indirectly, any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of capital stock for a period of 60&#160;days from the date of this prospectus. See &#8220;Underwriting&#8221; for more information. </font>
          </div>
          <div style="width:144pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:4pt; line-height:12pt;font-weight:bold;">
              <font style="letter-spacing:-0.2pt;">The Nasdaq Global Market symbol</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
            </div>
          </div>
          <div style="margin-left:168pt; margin-top:-12pt; width:288pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8220;GANX.&#8221; There is no established trading market for the Warrants, and we do not expect a market to develop. We do not intend to apply for a listing for any such warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the Warrants will be limited.</font>
          </div>
          <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The number of shares of our common stock that will be outstanding after this offering is based on 18,041,231 shares outstanding as of March&#160;31, 2024, which does not include the following, all as of March&#160;31, 2024: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">4,519,750 shares of common stock issuable upon the exercise of outstanding warrants to purchase shares of common stock with a weighted-average exercise price of $3.35 per share; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">368,910 shares of common stock issuable upon the vesting of outstanding restricted stock&#160;units; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">3,530,816 shares of common stock issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $4.45 per share; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">414,427 shares reserved for future issuances under our equity compensation plans. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:5pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Except as otherwise noted, all information in this prospectus assumes no exercise by the underwriter of its option to purchase additional shares of common stock from us, the exercise in full of all Pre-Funded Warrants sold in this offering, no exercise of the Underwriter Warrants, and no exercise of outstanding options or warrants to purchase common stock and no issuance of shares available for future issuance under our equity compensation plans; and reflects all currency in U.S. dollars.</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRIFA1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should carefully consider the risk factors we describe in this prospectus supplement and in any related free writing prospectus that we may authorize to be provided to you or in any report incorporated by reference into this prospectus supplement, including our <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1819411/000155837024003943/ganx-20231231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2023</a>, any Quarterly Report on Form 10-Q or any other filing by us with the SEC that is incorporated by reference into this prospectus supplement. Although we discuss key risks in those risk factor descriptions, additional risks not currently known to us or that we currently deem immaterial also may impair our business. Our subsequent filings with the SEC may contain amended and updated discussions of significant risks. We cannot predict future risks or estimate the extent to which they may affect our financial performance. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Associated with this Offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have broad discretion in the use of the net proceeds of this offering and may not use them effectively.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We intend to use the net proceeds of this offering to continue clinical and nonclinical development of our lead product candidate GT-02287 for the treatment of neurodegenerative diseases, including GBA1 Parkinson&#8217;s disease, and for general corporate purposes. However, our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Following this offering, we will require additional capital to finance our operations and achieve our goals. If we are unable to raise capital when needed or on terms acceptable to us, we may be forced to delay, reduce or eliminate our research or product development programs, any future commercialization efforts or other operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes&#160;years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance our lead product candidates and any future product candidates through clinical development. We will require substantial additional funding following this offering in order, among other things, to further advance our programs, including conducting additional clinical and regulatory development activities. We expect increased expenses as we continue our research and development, initiate additional clinical trials, seek to expand our product pipeline, seek marketing approval for our lead programs and future product candidates, if any, and invest in our organization. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Furthermore, we have incurred and will continue to incur additional costs associated with operating as a public company, such as acquiring and retaining experienced personnel, developing new information technology systems, and other costs associated with being a public company. Also, we expect to experience ongoing and additional costs related to preparing and filing patent applications, maintaining our intellectual property and potentially expanding our office facilities. Accordingly, following this offering, we will require substantial additional capital in connection with our continuing operations. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Adequate additional financing may not be available to us on favorable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. If we are unable to raise capital when needed or on favorable terms, we could be forced to delay, reduce or eliminate our research and development programs, our commercialization plans or other operations. Our ability to raise capital may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from inflation, changes in interest rates, recent turmoil in the global banking system, geopolitical instability, including the war in Ukraine, the Middle East and public health epidemics. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If you purchase shares of our common stock sold in this offering, you will experience immediate and substantial dilution.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The price of our common stock to be sold in this offering is substantially higher than the net tangible book value per share of our common stock. If you purchase shares of our common stock in this offering (or pre-funded warrants at the public offering price less $0.0001), you will experience immediate dilution of $&#8199;&#8199;&#8199;&#8199;&#8199; per share, representing the difference between as adjusted net tangible book value per share after giving effect to the sale by us of shares in this offering at the public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; per share. See the section entitled &#8220;Dilution&#8221; below for a more detailed discussion of the dilution you will incur if you purchase common stock in this offering. Further, we have a significant number of options and restricted stock outstanding. If the holders of these securities exercise them or become vested in them, as applicable, you may incur further dilution. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, in order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may be the same or lower than the price per share in this offering. We may not be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock or securities convertible into common stock in future transactions may be higher or lower than the price per share in this offering. You will incur dilution upon exercise of any outstanding stock options, warrants or upon the issuance of shares of common stock under our stock incentive programs. In addition, the sale of shares in this offering and any future sales of a substantial number of shares of our common stock in the public market, or the perception that such sales may occur, could adversely affect the price of our common stock. We cannot predict the effect, if any, that market sales of those shares of common stock or the availability of those shares of common stock for sale will have on the market price of our common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The market price for our common stock has been and likely will continue to be volatile, and your investment in our securities could decline in value.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our stock price has been highly volatile since our initial public offering and is likely to continue to be volatile. The stock market in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme price and volume fluctuations that have been often unrelated or disproportionate to the operating performance of the issuer. In the past, securities class action litigation has often been brought against companies that experience volatility in the market price of their securities and in particular, biotechnology and pharmaceutical companies. Whether or not meritorious, litigation brought against us could result in substantial costs and a diversion of management&#8217;s attention and resources, which could adversely affect our business, operating results and financial condition. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Stock market volatility and declines in the price of our common stock also increase the likelihood that we may fail to meet the minimum price requirements for continued listing on the Nasdaq Global Market. If the Nasdaq Global Market delists our securities from trading on its exchange for failure to meet the listing standards, we and our stockholders could face significant negative consequences, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Limited availability of market quotations for our securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">A determination that the common stock is a &#8220;penny stock&#8221; which will require brokers trading in the common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for shares of common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">A limited amount of analyst coverage; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">A decreased ability to issue additional securities or obtain additional financing in the future. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Sales of a substantial number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities. We may issue and sell additional shares of our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">common stock in the public markets including, without limitation, through our &#8220;at-the-market&#8221; offering program, underwritten public offerings, privately negotiated transactions, block trades, or any combination of the above. We cannot predict the effect that future sales of our common stock would have on the market price of our common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">There is substantial doubt about our ability to continue as a going concern. We have a history of operating losses and expect to incur losses for the foreseeable future. We may never generate revenues or, if we are able to generate revenues, achieve profitability.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We are focused on product development, and we have not generated any significant revenues to date. We have incurred losses in each year of our operations, and we expect to continue to incur operating losses for the foreseeable future. Since our inception we have incurred operating losses which have adversely affected and are likely to continue to adversely affect our working capital, total assets and shareholders&#8217; equity. In addition, the impact of these events and conditions on our liquidity raise substantial doubt about our ability to continue as a going concern. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We plan to raise additional capital primarily through public and/or private equity financings and/or convertible debt financings. However, financing may not be available to us in the necessary time frame, in amounts that we require, on terms that are acceptable to us, or at all. If we are unable to raise the necessary funds when needed, it may materially and adversely impact our ability to execute on our operating plans. If we become unable to continue as a going concern, we may have to dispose of assets and might realize significantly less than the values at which they are carried on our consolidated financial statements. These actions may cause our stockholders to lose all or part of their investment in our common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We and our prospects should be examined in light of the risks and difficulties frequently encountered by new and early-stage companies in new and rapidly evolving markets. These risks include, among other things, the speed at which we can scale up operations, our complete dependence upon development of our product candidates that currently have no market acceptance, our ability to establish and expand our brand name, our development of and reliance on strategic and customer relationships and our ability to minimize fraud and other security risks. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The process of developing our product candidates requires significant time, effort and expenses in preclinical, clinical and regulatory development. In addition, commercialization of our product candidates will require that we obtain necessary regulatory approvals and establish sales, marketing and manufacturing capabilities, either through internal hiring or through contractual relationships with others. We expect to incur substantial additional operating expenses over the next several&#160;years as our research, development, preclinical studies and clinical trial activities increase. Product candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will continue to increase in the foreseeable future as we (i)&#160;increase personnel costs, including stock-based compensation, (ii)&#160;continue preclinical development of our lead compounds, (iii)&#160;initiate clinical trials for certain product candidates, (iv)&#160;continue to discover and develop additional product candidates, and (v)&#160;pursue later stages of clinical development of product candidates. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The amount of future losses and when, if ever, we will achieve profitability are uncertain. We have no products that have generated any commercial revenue, do not expect to generate revenues from the commercial sale of products in the foreseeable future, and might never generate revenues from the sale of products. Our ability to generate revenue and achieve profitability will depend on, among other things, successful completion of preclinical development and testing and clinical trials of our product candidates; obtaining necessary regulatory approvals from the FDA and comparable foreign regulatory authorities; establishing manufacturing, sales and marketing arrangements with third parties; successfully commercializing our products; establishing a favorable competitive position; and raising sufficient funds to finance our activities. Many of these factors will depend on circumstances beyond our control. We might not succeed at any of these undertakings. If we are unsuccessful at some or all of these undertakings, our business, prospects and results of operations may be materially adversely affected. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:52pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Because we do not intend to declare cash dividends on our shares of common stock in the foreseeable future, stockholders must rely on appreciation of the value of our common stock for any return on their investment.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have never declared or paid cash dividends on our common stock and do not expect to do so in the foreseeable future. The declaration of dividends is subject to the discretion of our board of directors and limitations under applicable law, and will depend on various factors, including our operating results, financial condition, future prospects and any other factors deemed relevant by our board of directors. You should not rely on an investment in our company if you require dividend income from your investment in our company. The success of your investment will likely depend entirely upon any future appreciation of the market price of our common stock, which is uncertain and unpredictable. There is no guarantee that our common stock will appreciate in value. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Significant holders or beneficial holders of shares of our common stock may not be permitted to exercise the Pre-Funded Warrants that they hold.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A holder (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 4.99% of our outstanding common stock immediately after exercise, which percentage may be changed at the holder&#8217;s election to a higher or lower percentage not in excess of 9.99%. As a result, you may not be able to exercise your Pre-Funded Warrants for shares of our common stock at a time when it would be financially beneficial for you to do so. In such a circumstance, you could seek to sell your Pre-Funded Warrants to realize value, but you may be unable to do so in the absence of an established trading market and due to applicable transfer restrictions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">There is no public market for the Warrants.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There is no established public trading market for the Warrants in this offering, and we do not expect a market to develop. In addition, the Warrants are not listed, and we do not intend to apply for listing of the Warrants on any securities exchange or trading system. Without an active market, the liquidity of the Warrants is limited, and investors may be unable to liquidate their investments in the Warrants. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">A Warrant does not entitle the holder to any rights as common stockholders until the holder exercises the Warrant forshares of our common stock.</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Until you acquire shares of our common stock upon exercise of your Warrants, the Warrants will not provideyou any rights as a common stockholder. Upon exercise of your Warrants, you will be entitled to exercise the rightsof a common stockholder only as to matters for which the record date occurs on or after the exercise date. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Warrants in this offering are speculative in nature.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Warrants in this offering do not confer any rights of common stock ownership on their holders, such as voting rights or the right to receive dividends, but rather merely represent the right to acquire shares of common stock at a fixed price during a fixed period of time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Moreover, following this offering, the market value of the Warrants, if any, is uncertain and there can be no assurance that the market value of the Warrants will equal or exceed their imputed offering price. There can also be no assurance that the market price of the common stock will ever equal or exceed the exercise price of the Warrants and, consequently, whether it will ever be profitable for holders of the Warrants to exercise the Warrants. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUOP1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:472pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We estimate that the net proceeds from this offering will be approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; million, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the Warrants issued in this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We intend to use the net proceeds of this offering to continue clinical and nonclinical development of our lead product candidate GT-02287 for the treatment of neurodegenerative diseases, including GBA1 Parkinson&#8217;s disease, and for general corporate purposes. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The timing and amounts of our actual expenditures will depend on several factors, including the progress of our research and development programs, the results of other pre-clinical and clinical studies and the timing and costs of regulatory approvals. Pending the uses described above, we will invest the net proceeds in short-term and long-term, investment grade, interest-bearing securities. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOSW">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF SECURITIES WE ARE OFFERING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are offering shares of our common stock in this offering. See &#8220;Description of Securities&#8221; in the accompanying prospectus for more information regarding our shares of common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Pre-Funded Warrants</font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The material terms and provisions of the Pre-Funded Warrants being issued in this offering are summarized below. The following description is subject to, and qualified in its entirety by, the form of Pre-Funded Warrant which will be filed as an exhibit to a Current Report on Form 8-K to be filed by us with the SEC in connection with this offering. You should review the form of Pre-Funded Warrant for a complete description of the terms and conditions applicable to the Pre-Funded Warrants.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Exercisability.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Pre-Funded Warrants are exercisable immediately and the holder of the Pre-Funded Warrant is entitled to exercise at any time until the Pre-Funded Warrant is exercised in full. The holder of the Pre-Funded Warrant is not entitled to return or refund all, or any portion of any prepaid aggregate exercise price under any circumstance for any reason whatsoever. The remaining unpaid exercise price per share of common stock under the Pre-Funded Warrant is $0.0001, subject to adjustment in accordance with the terms of the Pre-Funded Warrants. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Exercise Limitation.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;A holder will not have the right to exercise any portion of the Pre-Funded Warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% (or 9.99% upon the request of the investor) of the number of common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. However, any holder may increase or decrease such percentage, provided that any increase will not be effective until the 61st day after such election. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Exercise Price.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Each pre-funded warrant offered hereby has an initial exercise price per share equal to $0.0001. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until the Pre- Funded Warrants are exercised in full. The exercise price and number of shares of common stock issuable upon exercise is subject to adjustment in the event of stock dividends, stock splits, stock combinations, reclassifications or similar events affecting our common stock. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Fundamental Transaction.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In the event of a fundamental transaction, as described in the Pre-Funded Warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding voting securities, the holders of the Pre-Funded Warrants will be entitled to receive upon exercise of the Pre-Funded Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants immediately prior to such fundamental transaction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Transferability.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Subject to applicable laws, a Pre-Funded Warrant may be transferred at the option of the holder upon surrender of the Pre-Funded Warrant to us together with the appropriate instruments of transfer. Exchange Listing. We do not intend to list the Pre-Funded Warrants on any securities exchange or nationally recognized trading system. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Rights as a Stockholder.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Except as otherwise provided in the Pre-Funded Warrants or by virtue of such holder&#8217;s ownership of, the holders of the Pre-Funded Warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their Pre-Funded Warrants. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Warrant Agent.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We will act as warrant agent for the pre-funded warrants. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Underwriter Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the closing of this offering, we have agreed to issue to the underwriter, or its designees, Underwriter Warrants to purchase a number of shares of common stock equal to an aggregate of 7% of the total number of shares and Pre-Funded Warrants sold in this public offering, including any shares of our common </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDIL">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">stock sold pursuant to the Dunderwriter&#39;s option to purchase additional shares of our common stock. The Underwriter Warrants will be exercisable at a per share exercise price equal to 125% of the offering price of the shares sold in this offering, or $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. The Underwriter Warrants are exercisable commencing six months after closing of this offering, and will be exercisable for a period of five years from the date of issuance. The Underwriter Warrants and the shares of common stock issuable upon the exercise thereof are being registered on the registration statement of which this prospectus supplement is a part. See &#8220;Underwriting &#8212; Underwriter Warrants&#8221; on page <a href="#UNWA">S-18</a> of this prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DILUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you invest in our securities, your interest will be diluted to the extent of the difference between the public offering price per share of common stock offered in this offering and the net tangible book value per share of our common stock immediately after this offering. Our net tangible book value as of March&#160;31, 2024 was $7.5&#160;million, or $0.42 per share. Net tangible book value per share is equal to our total assets (excluding internal-use software, pre-payments and deferred costs), less our total liabilities, divided by the total number of shares outstanding as of March&#160;31, 2024. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">After giving effect to the sale of the common stock in this offering (which assumes the exercise of all Pre-Funded Warrants sold in this offering and no exercise of the Underwriter Warrants) at an offering price of $ per share, and excluding the proceeds, if any, from the exercise of the Underwriter Warrants issued in this offering, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our net tangible book value as of March&#160;31, 2024 would have been $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, or approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share of common stock. This represents an immediate increase in net tangible book value of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share to our existing stockholders and an immediate dilution in net tangible book value of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share to new investors in this offering. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table illustrates this calculation on a per share basis: </font>
        </div>
        <table style="width:456pt;height:71pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:379.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Public offering price per share </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:379.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net tangible book value per share as of March&#160;31, 2024 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">0.42</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:379.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Increase in net tangible book value per share attributable to the offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:379.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">As adjusted net tangible book value per share after giving effect to the offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:379.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dilution in net tangible book value per share to new investors </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the underwriter exercises in full its option to purchase additional shares of common stock in this offering, our net tangible book value after the offering would be $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, or approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the increase in the net tangible book value to existing stockholders would be $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, and the dilution to new investors purchasing securities in this offering would be $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The number of shares of our common stock to be outstanding immediately after this offering is based on 18,041,231 shares of our common stock outstanding as of March&#160;31, 2024, and excludes the following, in each case as of such date: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">4,519,750 shares of common stock issuable upon the exercise of outstanding warrants to purchase shares of common stock with a weighted-average exercise price of $3.35 per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">368,910 shares of common stock issuable upon the vesting of outstanding restricted stock&#160;units; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">3,530,816 shares of common stock issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $4.45 per share; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">414,427 shares reserved for future issuances under our equity compensation plans. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the extent that any options are exercised, new options are issued under our equity incentive plans or we otherwise issue additional shares of common stock in the future at a price less than the public offering price, there will be further dilution to new investors.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUND1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UNDERWRITING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have entered into an underwriting agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC, or the underwriter, with respect to the securities subject to this offering. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Subject to certain conditions, we have agreed to sell to the underwriter such securities listed next to its name in the below table at the public offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus supplement. </font>
        </div>
        <table style="width:456pt;height:41.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:328pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">UNDERWRITER </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:50.09pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">NUMBER OF </font>
                <br >
                <font style="letter-spacing:-0.16pt;">SHARES</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:53.92pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">NUMBER OF</font>
                <br >
                <font style="letter-spacing:-0.16pt;">PRE-FUNDED</font>
                <br >
                <font style="letter-spacing:-0.16pt;">WARRANTS</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.167pt 0pt; width:328pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Titan Partners Group LLC, a division of American Capital Partners, LLC </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:50.09pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:53.92pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The underwriting agreement provides that the obligation of the underwriter to purchase the shares of common stock and Pre-Funded Warrants offered by this prospectus supplement and the accompanying prospectus is subject to certain conditions. The underwriter is obligated to purchase all of the shares of common stock and Pre-Funded Warrants offered hereby other than those covered by the over-allotment option described below. The underwriter is offering the securities, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel, and other conditions contained in the underwriting agreement. The underwriter reserves the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Over-Allotment Option</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have granted the underwriter an option to buy up to an additional &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of common stock from us at the public offering price less the underwriting discounts and commissions, to cover over-allotments, if any. The underwriter may exercise this option at any time, in whole at any time or in part from time to time, during the 30-day period after the date of this prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Discounts, Commissions and Expenses</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The underwriter proposes to offer the shares of common stock and Pre-Funded Warrants purchased pursuant to the underwriting agreement to the public at the public offering price set forth on the cover page of this prospectus supplement and to certain dealers at that price less a concession not in excess of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share. After this offering, the public offering price and concession may be changed by the underwriter. No such change shall change the amount of proceeds to be received by us as set forth on the cover page of this prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with the sale of the common stock to be purchased by the underwriter, the underwriter will be deemed to have received compensation in the form of underwriting commissions and discounts. The underwriting commissions and discounts will be 7.0% of the gross proceeds of this offering, or $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share of common stock, based on the public offering price per share set forth on the cover page of this prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will also be responsible for and will pay all expenses relating to the offering, including without limitation, reasonable out-of-pocket expenses incurred by the underwriter that we have agreed to reimburse the underwriter up to a maximum amount of $125,000, including the reasonable fees and disbursements of its counsel. We have also agreed to pay the underwriter a non-accountable expense allowance in the amount of one-half&#160;percent (0.5%) of the gross proceeds from this offering, or $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have also paid an advance of $15,000 to the underwriter, which will be applied against the accountable expenses that will be paid by us to the underwriter in connection with this offering. This payment will be returned to us to the extent not actually incurred by the underwriter in accordance with Rule&#160;5110(g)(4)(A) of the Financial Industry Regulatory Authority, or FINRA. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We estimate that our total offering expenses for this offering, net of the underwriting discounts and commissions, will be approximately $0.3 million. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="UNWA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes the underwriting discounts and commissions and proceeds, before expenses, to us assuming both no exercise and full exercise by the underwriter of the over-allotment option: </font>
        </div>
        <table style="width:416pt;height:71.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:234.39pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Price Per </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Price Per </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Pre-Funded</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Warrant</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
                <br >
                <font style="letter-spacing:-0.16pt;">without </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Option </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total with </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Option </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:234.39pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Public offering price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.58pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0.58pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.37pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199; </td>
            <td style="padding:0pt;padding-left:4.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:1.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234.39pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Underwriting discounts and commissions</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.58pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0.58pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.37pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:4.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:1.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234.39pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Proceeds, before expenses, to us</font><font style=" position:relative; bottom:4.25pt;font-size:6.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.58pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0.58pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.37pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21.75pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:4.37pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.85pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.85pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.7pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The underwriting discount is 7.0% of the gross proceeds received from the sale of the securities in this offering. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:20pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">The amount of the offering proceeds to us presented in this table does not give effect to the exercise, if any, of the Warrants being issued in connection with this offering. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Underwriter Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the closing of this offering, we have agreed to issue to the underwriter, or its designees, Underwriter Warrants to purchase a number of shares of common stock equal to an aggregate of 7% of the total number of shares of common stock and Pre-Funded Warrants sold in this public offering, including any shares of our common stock sold pursuant to the underwriter&#39;s option to purchase additional shares of our common stock. The Underwriter Warrants will be exercisable at a per share exercise price equal to 125% of the offering price of the shares sold in this offering, or $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. The Underwriter Warrants are exercisable commencing six&#160;months after closing of this offering, and will be exercisable for a period of five&#160;years from the date of issuance. The Underwriter Warrants and the shares of common stock issuable upon the exercise thereof are being registered on the registration statement of which this prospectus supplement is a part. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Underwriter Warrants and the shares of common stock underlying the Underwriter Warrants have been deemed compensation by FINRA, and are therefore subject to a 180-day lock-up pursuant to Rule&#160;5110(e)(1) of FINRA. Neither the underwriter nor its permitted assignees under such rule, may sell, transfer, assign, pledge, or hypothecate the Underwriter Warrants or the securities underlying the Underwriter Warrants, nor will the underwriter engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the Underwriter Warrants or the underlying shares for a period of 180&#160;days from the effective date of the registration statement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Additionally, the Underwriter Warrants may not be sold, transferred, assigned, pledged or hypothecated for a 180-day period following the effective date of the registration statement except to any underwriter and selected dealer participating in this offering and their bona fide officers or partners. The Underwriter Warrants will provide for adjustment in the number and price of the Underwriter Warrants and the shares of common stock underlying such Underwriter Warrants in the event of recapitalization, merger, stock split or other structural transaction, or a future financing undertaken by us. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Indemnification</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have also agreed to indemnify the underwriter against certain liabilities, including civil liabilities under the Securities Act and to contribute to payments that the underwriter may be required to make in respect of those liabilities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Lock-Up Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have agreed that, for a period of sixty (60) days after from the closing of this offering, without the prior written consent of the underwriter, and subject to certain exceptions, neither we nor any of our subsidiaries shall issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of our common stock or common stock equivalents or file any registration statement or amendment or supplement thereto, other than this prospectus supplement. We have also agreed that from the date of the underwriting agreement until the six-month anniversary of the closing of this offering, without the prior </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">consent of the underwriter, we will not undertake any offering of our securities involving a &#8220;Variable Rate Transaction&#8221; &#8203;(as defined in the underwriting agreement). </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, each of our directors and officers has entered into a lock-up agreement with the underwriter. Under the lock-up agreements, for a period of sixty (60) days from the closing of this offering, without the prior written consent of the underwriter, the foregoing persons may not, subject to certain exceptions, offer, sell, contract to sell, lend, hypothecate, pledge or otherwise dispose of (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition, whether by actual disposition or effective economic disposition due to cash settlement or otherwise, by such person or any affiliate or any person in privity with such person), directly or indirectly, any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of capital stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Electronic Distribution</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement and the accompanying prospectus may be made available in electronic format on websites or through other online services maintained by the underwriter or by its affiliates. In those cases, prospective investors may view offering terms online and prospective investors may be allowed to place orders online. Other than this prospectus supplement and the accompanying prospectus in electronic format, the information on the underwriter&#8217;s website or our website and any information contained in any other websites maintained by the underwriter or by us is not part of this prospectus supplement, the accompanying prospectus or the registration statement of which this prospectus supplement and the accompanying prospectus form a part, has not been approved and/or endorsed by us or the underwriter in its capacity as the underwriter, and should not be relied upon by investors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Passive Market Making</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with this offering, the underwriter and selling group members may also engage in passive market making transactions in our common stock. Passive market making consists of displaying bids limited by the prices of independent market makers and effecting purchases limited by those prices in response to order flow. Rule&#160;103 of Regulation&#160;M promulgated by the SEC limits the amount of net purchases that each passive market maker may make and the displayed size of each bid. Passive market making may stabilize the market price of the shares of common stock at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Nasdaq Capital Market Listing</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is listed on Nasdaq Global Market under the symbol &#8220;GANX.&#8221; The last reported sale price of our common stock on June 11, 2024 was $2.43 per share. There is no established trading market for the Warrants, and we do not expect a trading market to develop. We do not intend to list the Warrants on any securities exchange or nationally recognized trading system. Without a trading market, the liquidity of the Warrants will be extremely limited.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Price Stabilization, Short Positions and Penalty Bids</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the offering, the underwriter may engage in stabilizing transactions, over-allotment transactions, syndicate covering transactions and penalty bids in accordance with Regulation&#160;M under the Exchange Act: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Over-allotment involves sales by the underwriter of shares in excess of the number of shares the underwriter is obligated to purchase, which creates a syndicate short position. The short position may be either a covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriter is not greater than the number of shares that they may purchase pursuant to the over-allotment option. In a naked short position, the number of shares involved is greater than the number of shares that the underwriter may purchase pursuant to the over-allotment option. The underwriter may close out any covered short position by either exercising the over-allotment option and/or purchasing shares in the open market. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Syndicate covering transactions involve purchases of the common stock in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of shares to close out the short position, the underwriter will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the over-allotment option. A naked short position occurs if the underwriter sell more shares than could be covered by the over-allotment option. This position can only be closed out by buying shares in the open market. A naked short position is more likely to be created if the underwriter is concerned that there could be downward pressure on the price of the shares in the open market after pricing that could adversely affect investors who purchase in the offering. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">Penalty bids permit the underwriter to reclaim a selling concession from a syndicate member when the common stock originally sold by the syndicate member is purchased in a stabilizing or syndicate covering transaction to cover syndicate short positions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of the common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. These transactions may be discontinued at any time. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Neither we nor the underwriter make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our shares of common stock. In addition, neither we nor the underwriter make any representation that the underwriter will engage in these transactions or that any transaction, if commenced, will not be discontinued without notice. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Relationships</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The underwriter is a full-service financial institution engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, principal investment, hedging, financing and brokerage activities. The underwriter and its affiliates may, from time to time, engage in transactions with and perform services for us in the ordinary course of its business for which it may receive customary fees and reimbursement of expenses. In the ordinary course of its various business activities, the underwriter and its affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (which may include bank loans and/or credit default swaps) for its own account and for the accounts of its customers and may at any time hold long and short positions in such securities and instruments. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriter and its affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Offer Restrictions Outside the United States</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Other than in the United States, no action has been taken by us or the underwriter that would permit a public offering of the securities offered by this prospectus supplement in any jurisdiction where action for that purpose is required. The securities offered by this prospectus supplement may not be offered or sold, directly or indirectly, nor may this prospectus supplement or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus supplement comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus supplement. This prospectus supplement does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus supplement in any jurisdiction in which such an offer or a solicitation is unlawful. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Australia</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus supplement is not a disclosure document under Chapter 6D of the Australian Corporations Act, has not been lodged with the Australian Securities and Investments Commission and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">does not purport to include the information required of a disclosure document under Chapter 6D of the Australian Corporations Act. Accordingly, (i)&#160;the offer of the securities under this prospectus supplement is only made to persons to whom it is lawful to offer the securities without disclosure under Chapter 6D of the Australian Corporations Act under one or more exemptions set out in section 708 of the Australian Corporations Act, (ii)&#160;this prospectus supplement is made available in Australia only to those persons as set forth in clause (i)&#160;above, and (iii)&#160;the offeree must be sent a notice stating in substance that by accepting this offer, the offeree represents that the offeree is such a person as set forth in clause (i)&#160;above, and, unless permitted under the Australian Corporations Act, agrees not to sell or offer for sale within Australia any of the securities sold to the offeree within 12&#160;months after its transfer to the offeree under this prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Canada</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument&#160;31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor. Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriter is not required to comply with the disclosure requirements of NI33-105 regarding underwriter conflicts of interest in connection with this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cayman Islands</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">No invitation, whether directly or indirectly, may be made to the public in the Cayman Islands to subscribe for our securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">European Economic Area&#8201;&#8212;&#8201;Belgium, Germany, Luxembourg and Netherlands</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The information in this document has been prepared on the basis that all offers of securities will be made pursuant to an exemption under the Directive 2003/71/EC, the Prospectus Directive, as implemented in Member States of the European Economic Area (each, a Relevant Member State), from the requirement to produce a prospectus for offers of securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">An offer to the public of securities has not been made, and may not be made, in a Relevant Member State except pursuant to one of the following exemptions under the Prospectus Directive as implemented in that Relevant Member State: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to legal entities that are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to any legal entity that has two or more of (i)&#160;an average of at least 250 employees during its last fiscal year; (ii)&#160;a total balance sheet of more than &euro;43,000,000 (as shown on its last annual unconsolidated or consolidated financial statements) and (iii)&#160;an annual net turnover of more than &euro;50,000,000 (as shown on its last annual unconsolidated or consolidated financial statements); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to fewer than 100 natural or legal persons (other than qualified investors within the meaning of Article&#160;2(1)(e) of the Prospectus Directive) subject to obtaining the prior consent of us or any underwriter for any such offer; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in any other circumstances falling within Article&#160;3(2) of the Prospectus Directive, provided that no such offer of securities shall result in a requirement for the publication by us of a prospectus pursuant to Article&#160;3 of the Prospectus Directive. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">France</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This document is not being distributed in the context of a public offering of financial securities (offre au public de titres financiers) in France within the meaning of Article&#160;L.411-1 of the French Monetary and Financial Code (Code Mon&#233;taire et Financier) and Articles 211-1 et seq. of the General Regulation of the French Autorit&#233; des march&#233;s financiers (&#8220;AMF&#8221;). The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This document and any other offering material relating to the securities have not been, and will not be, submitted to the AMF for approval in France and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in France. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Such offers, sales and distributions have been and shall only be made in France to (i)&#160;qualified investors (investisseurs qualifi&#233;s) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2&#176; and D.411-1 to D.411-3, D.744-1, D.754-1 ;and D.764-1 of the French Monetary and Financial Code and any implementing regulation and/or (ii)&#160;a restricted number of non-qualified investors (cercle restreint d&#8217;investisseurs) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2&#176; and D.411-4, D.744-1, D.754-1; and D.764-1 of the French Monetary and Financial Code and any implementing regulation. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to Article&#160;211-3 of the General Regulation of the AMF, investors in France are informed that the securities cannot be distributed (directly or indirectly) to the public by the investors otherwise than in accordance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 to L.621-8-3 of the French Monetary and Financial Code. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Ireland</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The information in this document does not constitute a prospectus under any Irish laws or regulations and this document has not been filed with or approved by any Irish regulatory authority as the information has not been prepared in the context of a public offering of securities in Ireland within the meaning of the Irish Prospectus (Directive 2003/71/EC) Regulations&#160;2005, or the Prospectus Regulations. The securities have not been offered or sold, and will not be offered, sold or delivered directly or indirectly in Ireland by way of a public offering, except to (i)&#160;qualified investors as defined in Regulation&#160;2(l) of the Prospectus Regulations and (ii)&#160;fewer than 100 natural or legal persons who are not qualified investors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Israel</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The securities offered by this prospectus supplement have not been approved or disapproved by the Israeli Securities Authority (the ISA), or ISA, nor have such securities been registered for sale in Israel. The shares may not be offered or sold, directly or indirectly, to the public in Israel, absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in connection with the offering or publishing the prospectus; nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered an opinion as to the quality of the securities being offered. Any resale in Israel, directly or indirectly, to the public of the securities offered by this prospectus supplement is subject to restrictions on transferability and must be effected only in compliance with the Israeli securities laws and regulations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Italy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The offering of the securities in the Republic of Italy has not been authorized by the Italian Securities and Exchange Commission (Commissione Nazionale per le Societ&#224; e la Borsa, &#8220;CONSOB&#8221; pursuant to the Italian securities legislation and, accordingly, no offering material relating to the securities may be distributed in Italy and such securities may not be offered or sold in Italy in a public offer within the meaning of Article&#160;1.1(t) of Legislative Decree No. 58 of 24 February&#160;1998 (&#8220;Decree No. 58&#8221;), other than: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to Italian qualified investors, as defined in Article&#160;100 of Decree no.58 by reference to Article&#160;34-ter of CONSOB Regulation no.&#160;11971 of 14 May&#160;1999 (&#8220;Regulation no.&#160;1197l&#8221;) as amended (&#8220;Qualified Investors&#8221;); and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in other circumstances that are exempt from the rules on public offer pursuant to Article&#160;100 of Decree No. 58 and Article&#160;34-ter of Regulation&#160;No. 11971 as amended. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any offer, sale or delivery of the securities or distribution of any offer document relating to the securities in Italy (excluding placements where a Qualified Investor solicits an offer from the issuer) under the paragraphs above must be: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">made by investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with Legislative Decree No. 385 of 1 September&#160;1993 (as amended), Decree No. 58, CONSOB Regulation&#160;No. 16190 of 29 October&#160;2007 and any other applicable laws; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in compliance with all relevant Italian securities, tax and exchange controls and any other applicable laws. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any subsequent distribution of the securities in Italy must be made in compliance with the public offer and prospectus requirement rules provided under Decree No. 58 and the Regulation&#160;No. 11971 as amended, unless an exception from those rules applies. Failure to comply with such rules may result in the sale of such securities being declared null and void and in the liability of the entity transferring the securities for any damages suffered by the investors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Japan</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The securities have not been and will not be registered under Article&#160;4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948), as amended (the &#8220;FIEL&#8221;) pursuant to an exemption from the registration requirements applicable to a private placement of securities to Qualified Institutional Investors (as defined in and in accordance with Article&#160;2, paragraph 3 of the FIEL and the regulations promulgated thereunder). Accordingly, the securities may not be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan other than Qualified Institutional Investors. Any Qualified Institutional Investor who acquires securities may not resell them to any person in Japan that is not a Qualified Institutional Investor, and acquisition by any such person of securities is conditional upon the execution of an agreement to that effect. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Portugal</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This document is not being distributed in the context of a public offer of financial securities (oferta p&#250;blica de valores mobili&#225;rios) in Portugal, within the meaning of Article&#160;109 of the Portuguese Securities Code (C&#243;digo dos Valores Mobili&#225;rios). The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in Portugal. This document and any other offering material relating to the securities have not been, and will not be, submitted to the Portuguese Securities Market Commission (Comiss&#259;o do Mercado de Valores Mobili&#225;rios) for approval in Portugal and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in Portugal, other than under circumstances that are deemed not to qualify as a public offer under the Portuguese Securities Code. Such offers, sales and distributions of securities in Portugal are limited to persons who are &#8220;qualified investors&#8221; (as defined in the Portuguese Securities Code). Only such investors may receive this document and they may not distribute it or the information contained in it to any other person. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sweden</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This document has not been, and will not be, registered with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority). Accordingly, this document may not be made available, nor may the securities be offered for sale in Sweden, other than under circumstances that are deemed not to require a prospectus under the Swedish Financial Instruments Trading Act (1991:980) (Sw. lag (1991:980) om handel med finansiella instrument). Any offering of securities in Sweden is limited to persons who are &#8220;qualified investors&#8221; &#8203;(as defined in the Financial Instruments Trading Act). Only such investors may receive this document and they may not distribute it or the information contained in it to any other person. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Switzerland</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#8220;SIX&#8221;) or on any other stock exchange or regulated trading facility in Switzerland. This </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:32pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering material relating to the securities may be publicly distributed or otherwise made publicly available in Switzerland. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither this document nor any other offering material relating to the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority (FINMA). </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This document is personal to the recipient only and not for general circulation in Switzerland. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">United Arab Emirates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither this document nor the securities have been approved, disapproved or passed on in any way by the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates, nor have we received authorization or licensing from the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates to market or sell the securities within the United Arab Emirates. This document does not constitute and may not be used for the purpose of an offer or invitation. No services relating to the securities, including the receipt of applications and/or the allotment or redemption of such shares, may be rendered within the United Arab Emirates by us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No offer or invitation to subscribe for securities is valid or permitted in the Dubai International Financial Centre. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">United Kingdom</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither the information in this document nor any other document relating to the offer has been delivered for approval to the Financial Conduct Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as amended (&#8220;FSMA&#8221;) has been published or is intended to be published in respect of the securities. This document is issued on a confidential basis to &#8220;qualified investors&#8221; &#8203;(within the meaning of section 86(7) of FSMA) in the United Kingdom, and the securities may not be offered or sold in the United Kingdom by means of this document, any accompanying letter or any other document, except in circumstances which do not require the publication of a prospectus pursuant to section 86(1) FSMA. This document should not be distributed, published or reproduced, in whole or in part, nor may its contents be disclosed by recipients to any other person in the United Kingdom. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) received in connection with the issue or sale of the securities has only been communicated or caused to be communicated and will only be communicated or caused to be communicated in the United Kingdom in circumstances in which section 21(1) of FSMA does not apply to us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the United Kingdom, this document is being distributed only to, and is directed at, persons (i)&#160;who have professional experience in matters relating to investments falling within Article&#160;19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (&#8220;FPO&#8221;), (ii) who fall within the categories of persons referred to in Article&#160;49(2)(a) to (d)&#160;(high net worth companies, unincorporated associations, etc.) of the FPO or (iii)&#160;to whom it may otherwise be lawfully communicated (together &#8220;relevant persons&#8221;). The investments to which this document relates are available only to, and any invitation, offer or agreement to purchase will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLEMA1">&#8203;</a><a name="tEXP1">&#8203;</a><a name="tWYCF1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:200pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The validity of the securities offered hereby will be passed upon by Lowenstein Sandler LLP, New York, New York. McGuireWoods LLP, New York, New York, is representing the underwriter. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The consolidated financial statements of Gain Therapeutics, Inc. appearing in Gain Therapeutics, Inc.&#8217;s <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1819411/000155837024003943/ganx-20231231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2023</a> have been audited by Ernst &amp; Young AG, independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have filed with the SEC a registration statement on Form S-3, including exhibits, under the Securities Act of which this prospectus supplement and the accompanying prospectus forms a part. This prospectus does not contain all of the information set forth in the registration statement. This prospectus supplement and the accompanying prospectus are a part of the registration statement but do not contain descriptions of certain agreements or documents that are exhibits to the registration statement. The statements as to the contents of such exhibits, however, are brief descriptions and are not necessarily complete, and each statement is qualified in all respects by reference to such agreement or document. For further information about us, please refer to the registration statement and the documents incorporated by reference in this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#8217;s website at </font><font style="font-style:italic;letter-spacing:0.2pt;">http://www.sec.gov</font><font style="letter-spacing:0.2pt;">. The SEC&#8217;s website contains reports, proxy statements and other information regarding issuers, such as Gain Therapeutics, Inc., that file electronically with the SEC. We make available free of charge through our web site our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, Proxy Statements on Schedule&#160;14A and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC. Our website address is </font><font style="font-style:italic;letter-spacing:0.2pt;">http://www.gaintherapeutics.com</font><font style="letter-spacing:0.2pt;">. Please note that our website address is provided as an inactive textual reference only. Information contained on or accessible through our website is not part of this prospectus or the prospectus supplement and is therefore not incorporated by reference unless such information is otherwise specifically referenced elsewhere in this prospectus or the prospectus supplement. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIODB1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION OF DOCUMENTS BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SEC allows us to &#8220;incorporate by reference&#8221; into this prospectus supplement, and the accompanying prospectus, the information we have filed with the SEC, which means that we can disclose important information to you by referring you to those documents. Any information that we file subsequently with the SEC will automatically update this prospectus supplement and the accompanying prospectus. We incorporate by reference into this prospectus supplement, and the accompanying prospectus, the information contained in the documents listed below, which is considered to be a part of this prospectus: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1819411/000155837024003943/ganx-20231231x10k.htm">our Annual Report on Form 10-K for the year ended December&#160;31, 2023, filed with the SEC on March&#160;26, 2024;</a> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the portions of our <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1819411/000155837024005893/tmb-20240624xdef14a.htm">definitive proxy statement on Schedule&#160;14A</a> incorporated by reference to our Annual Report on Form 10-K for the year ended December&#160;31, 2023, as filed with the SEC on April&#160;26, 2024; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1819411/000155837024008132/ganx-20240331x10q.htm">our Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2024, filed with the SEC on May&#160;14, 2024;</a> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our Current Reports on Form 8-K filed with the SEC on <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1819411/000110465924026302/tm245020d2_8k.htm">February&#160;22, 2024</a> and <a style="-sec-extract:exhibit" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1819411/000110465924044750/tm2411246d1_8k.htm">April&#160;8, 2024;</a> and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the description of our common stock contained in <a style="-sec-extract:exhibit" href="https://www.sec.gov/Archives/edgar/data/1819411/000155837024003943/ganx-20231231xex4d1.htm">Exhibit&#160;4.1</a> to our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2023, filed with the SEC on March&#160;26, 2024, and any amendment or report filed for the purpose of updating such description. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We also incorporate by reference all documents we file under Sections&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act filed after the date of this prospectus supplement. The most recent information that we file with the SEC automatically updates and supersedes older information. The information contained in any such filing will be deemed to be a part of this prospectus, commencing on the date on which the document is filed. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Notwithstanding the statements in the preceding paragraphs, no document, report or exhibit (or portion of any of the foregoing) or any other information that we have &#8220;furnished&#8221; to the SEC pursuant to the Securities Exchange Act of 1934, as amended shall be incorporated by reference into this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will furnish without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any documents incorporated by reference other than exhibits to those documents. Requests should be addressed to: </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Corporate Secretary</font>
          <br >
          <font style="letter-spacing:0.2pt;">Gain Therapeutics, Inc.</font>
          <br >
          <font style="letter-spacing:0.2pt;">4800 Montgomery Lane, Suite 220,</font>
          <br >
          <font style="letter-spacing:0.2pt;">Bethesda, Maryland 20814</font>
          <br >
          <font style="letter-spacing:0.2pt;">(301) 500-1556 </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any statement contained in this prospectus supplement or in a document incorporated or deemed to be incorporated by reference into this prospectus supplement will be deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained in this prospectus supplement or any other subsequently filed document that is deemed to be incorporated by reference into this prospectus supplement modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should rely only on information contained in, or incorporated by reference into, this prospectus supplement and the accompanying prospectus. We have not authorized anyone to provide you with information different from that contained in this prospectus supplement and the accompanying prospectus or incorporated by reference in this prospectus supplement and the accompanying prospectus. We are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">S-26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:6pt; text-align:center; width:456pt;">
          <img src="lg_gaintherapeutics-4c.jpg" alt="[MISSING IMAGE: lg_gaintherapeutics-4c.jpg]" height="93" width="196" >
        </div>
        <div style="margin-top:16.2pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">$100,000,000</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">Common Stock </font>
          <br >
          <font style="letter-spacing:-0.28pt;">Preferred Stock </font>
          <br >
          <font style="letter-spacing:-0.28pt;">Debt Securities </font>
          <br >
          <font style="letter-spacing:-0.28pt;">Warrants</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">From time to time, we may offer up to $100,000,000 of any combination of the securities described in this prospectus in one or more offerings. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable antidilution provisions. </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">This prospectus provides a general description of the securities we may offer. Each time we offer securities, we will provide specific terms of the securities offered in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before you invest in any of the securities being offered. </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">This prospectus may not be used to consummate a sale of any securities unless accompanied by a prospectus supplement.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is listed on The Nasdaq Global Market, or Nasdaq, under the symbol &#8220;GANX.&#8221; On May&#160;13, 2022, the last reported sale price of our common stock was $2.69 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing on Nasdaq or any securities market or other exchange of the securities, if any, covered by the prospectus supplement. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement of which this prospectus is a part in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0&#160;million. As of the date hereof, we have not offered any securities pursuant to General Instruction I.B.6 of Form&#160;S-3 during the 12 calendar&#160;months prior to and including the date of this prospectus. </font>
        </div>
        <div style="text-indent:20pt; margin-top:4pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">We will sell these securities directly to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section titled &#8220;Plan of Distribution&#8221; in this prospectus. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts or over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. </font>
        </div>
        <div style="margin-top:9.7pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:7.19pt; width:456pt; line-height:11pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus as described on page <a href="#tRIFA">7</a> of this prospectus.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:9.7pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:7.2pt; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </font>
        </div>
        <div style="margin-top:9.7pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:27.19pt; text-align:center; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">The date of this prospectus is June 1, 2022.</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC3">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:205pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tATP"><font style="letter-spacing:0.2pt;">ABOUT THIS PROSPECTUS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tATP">i</a></font> <a href="#tATP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSUM"><font style="letter-spacing:0.2pt;">SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSUM">1</a></font> <a href="#tSUM"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tRIFA">7</a></font> <a href="#tRIFA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tSNRF"><font style="letter-spacing:0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tSNRF">8</a></font> <a href="#tSNRF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tUOP">10</a></font> <a href="#tUOP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOCS"><font style="letter-spacing:0.2pt;">DESCRIPTION OF CAPITAL STOCK </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOCS">11</a></font> <a href="#tDOCS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDODS"><font style="letter-spacing:0.2pt;">DESCRIPTION OF DEBT SECURITIES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDODS">15</a></font> <a href="#tDODS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tDOW"><font style="letter-spacing:0.2pt;">DESCRIPTION OF WARRANTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tDOW">22</a></font> <a href="#tDOW"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLOOS"><font style="letter-spacing:0.2pt;">LEGAL OWNERSHIP OF SECURITIES </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLOOS">24</a></font> <a href="#tLOOS"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tPOD"><font style="letter-spacing:0.2pt;">PLAN OF DISTRIBUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tPOD">27</a></font> <a href="#tPOD"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tLEMA">29</a></font> <a href="#tLEMA"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tEXP">29</a></font> <a href="#tEXP"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tWYCF">30</a></font> <a href="#tWYCF"></a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:434pt;text-align:left;">
              <div style="white-space:nowrap;">
                <a href="#tIOCI"><font style="letter-spacing:0.2pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:10.5pt; text-align:right; white-space:nowrap;">
              <font style="letter-spacing:0.2pt;"><a href="#tIOCI">31</a></font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tATP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:8pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">ABOUT THIS PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is a part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or SEC, utilizing a &#8220;shelf&#8221; registration process. Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one or more offerings up to a total aggregate offering price of $100,000,000. This prospectus provides you with a general description of the securities we may offer. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each time we sell securities under this prospectus, we will provide a prospectus supplement that will contain specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should read this prospectus, any applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the heading &#8220;Incorporation of Certain Information by Reference,&#8221; before investing in any of the securities offered. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither we, nor any agent, underwriter or dealer has authorized any person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus prepared by or on behalf of us or to which we have referred you. This prospectus, any applicable supplement to this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, any applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus and the information incorporated herein by reference contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#8220;Where You Can Find More Information.&#8221; </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless the context indicates otherwise, references in this prospectus to &#8220;Gain&#8221;,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar references refer to Gain Therapeutics, Inc. and its wholly owned subsidiaries. Our name &#8220;Gain Therapeutics&#8221; the Gain logo and other trademarks, trade names or service marks of Gain Therapeutics, Inc. appearing in this prospectus are the property of Gain Therapeutics, Inc. All other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the </font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> and &#8482; symbols, but such references should not be construed as any indicator that their respective owners will not assert their rights thereto.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSUM">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">The following summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our consolidated financial statements, and the exhibits to the registration statement of which this prospectus is a part.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Company Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutics areas, including, lysosomal storage disorders, or LSDs, central nervous system disorders, or CNS, metabolic disorders, and oncology. We use our exclusively in-licensed computational target and drug discover platform, Site-Directed Enzyme Enhancement Therapy, or SEE-Tx</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, to discover novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function, and treat the underlying cause of the disease. These binding sites, distinct from the protein&#8217;s active site, are called allosteric sites. We believe that targeting an allosteric binding site instead of the active binding site of a protein provides numerous advantages: the ability to regulate proteins implicated in disease through several different mechanisms of action covering both functional and conformational effects, including stabilization, destabilization, targeted degradation, allosteric inhibition, and allosteric activation of the targeted protein; improved specificity of small molecules because binding to an allosteric binding site is non-competitive with the natural substrate that binds to the active binding site; and the ability to identify small molecules with more favorable drug-like properties. The SEE-Tx</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> platform has been used to identify novel allosteric sites and small molecules for all of our internal and partnered programs. Discovering and targeting novel allosteric sites with our platform not only collapses traditional drug discovery timelines but enables rational drug design and offers the potential for superior small molecule drugs that are highly specific and that can penetrate hard to reach tissues and cross the blood-brain barrier. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We have filed four patent applications for our novel small molecule drug candidates that are Structurally Targeted Allosteric Regulators, or STARs. In June&#160;2021, the Company announced the publication of two PCT patents. The first was directed at compounds targeting misfolded beta-glucocerebrosidase, or GBA, addressing CNS diseases such as Parkinson&#8217;s disease, Gaucher disease, Alzheimer&#8217;s disease, and Lewy body dementia. The second was directed at compounds targeting galactosylceramidase, or GALC, addressing demyelinating disorders such as Krabbe disease and multiple sclerosis. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We have identified two different STARs as the lead compounds for our Parkinson&#8217;s disease program and our Gaucher disease program and are currently developing these product candidates through preclinical studies. In September&#160;2021, the Company announced positive topline data of an in vitro study evaluating the two STARs for the treatment of Gaucher and Parkinson&#8217;s disease in neuronal cells derived induced pluripotent stem cells, or iPSCs, of a a patient with Gaucher disease that contained the disease-causing mutation of the GBA1 gene and from iPSCs of a healthy donor with a normal GBA1 gene, so called wild-type cells. The results of the study, conducted at the University of Maryland School of Medicine, demonstrate a significant increase in beta-glucocerebrosidase, or GCase, protein levels, improved trafficking of GCase to the lysosome, and a significant decrease of toxic substrates glucosylceramide and alpha-synuclein p129 levels in both the neuronal cells that contained the mutated GBA1 gene as well as the wild-type cells. Alpha synuclein is consididered to be the hallmark of Parkinson&#8217;s disease. In addition, these data provides further evidence that these product candidates have the potential to treat Gaucher disease and Parkinson&#8217;s disease and slow or stop the progression of GBA Parkinson&#8217;s disease. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We expect to complete the preclinical development and submit the regulatory dossier to the Human Research Ethics Committee in Australia to initiate a first-in-human Phase&#160;1 clinical trial in our Parkinson&#8217;s disease program, and to initiate the preclinical toxicology studies for our Gaucher program in the second half of 2022. In addition, we plan to continue to advance research programs and initiate additional programs </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:11pt;">
            <font style="letter-spacing:0.2pt;">targeting allosteric binding sites identified with the SEE-Tx</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> platform. Through academic partnerships, co-development and licensing arrangements, we intend to develop a broad pipeline of therapeutics, using our novel approach of identifying and targeting previously unknown allosteric sites. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Pipeline of STARs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are leveraging our SEE-Tx technology platform and the technology underlying we in-licensed to develop a pipeline of novel drug candidates to address diseases caused by protein misfolding. We are initially focusing on several LSDs with high unmet medical need, with the ability to expand our pipeline as we continue to discover new targets. We have entered into a number of academic collaborations to advance the development of our programs, such as with the University of Minnesota and the University of Maryland; these collaborations are understandings to work together in the research of specific demyelinating diseases and neither we, nor the institutions we collaborate with, are under contractual obligations to continue the collaboration and all parties retain their respective intellectual property. </font>
          </div>
          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The following table sets forth the status of our product candidates: </font>
          </div>
          <div style="position:relative;margin-top:9.5pt; text-align:center; width:456pt;">
            <img src="fc_product-4clr.jpg" alt="[MISSING IMAGE: fc_product-4clr.jpg]" height="252" width="568" >
          </div>
          <div style="margin-top:16pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Risks Associated with Our Business</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our business is subject to numerous risks. You should read these risks before you invest in our securities. In particular, our risks include, but are not limited to, the following: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We have a history of operating losses and expect to incur losses for the foreseeable future. We may never generate revenues or, if we are able to generate revenues, achieve profitability. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We have a limited operating history and we expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">If preclinical studies or clinical trials for our product candidates cannot be initiated or completed or if they are unsuccessful or delayed, we will be unable to meet our future development and commercialization goals. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">The disorders we seek to treat have low prevalence and it may be difficult to identify patients with these disorders, which may lead to delays in enrollment for our trials or slower commercial revenue, if approved. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Our product candidates are novel and still in development. If we are unable to successfully develop, receive regulatory approval for and commercialize our current or future product candidates, our business will be harmed. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We have not tested any of our product candidates in clinical trials. Success in early preclinical studies or clinical trials may not be indicative of results obtained in later preclinical studies and clinical trials. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">The approach we are taking to discover and develop our product candidates is novel and may never lead to marketable products. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Clinical trials required for our product candidates are expensive and time-consuming, may face enrollment challenges and their outcome is uncertain. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Our business and operations may be adversely affected by the evolving and ongoing COVID-19 global pandemic. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We are subject to extensive and costly government regulation. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">Even if we obtain regulatory approval to market our product candidates, our product candidates may not be accepted by the market. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We rely on a license to use the technology underlying SEE-Tx technology platform that is material to our business and if the agreements underlying the licenses were to be terminated or if other rights that may be necessary for commercializing our intended products cannot be obtained, it would halt our ability to market our products and technology, as well as have an immediate material adverse effect on our business, operating results and financial condition. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We intend to rely on third parties to manufacture the compounds used in our studies, and we intend to rely on them for the manufacture of any approved products for commercial sale. If these third parties do not manufacture our product candidates in sufficient quantities and at an acceptable cost, clinical development and commercialization of our product candidates could be delayed, prevented or impaired. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">We have identified a material weakness in our internal control over financial reporting and may identify additional material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements in our financial statements. If we fail to remediate our material weakness, we may not be able to report our financial results timely and accurately or to prevent fraud. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Corporate Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We were incorporated under the laws of the state of Delaware on June&#160;26, 2020 under the name Gain&#160;Therapeutics, Inc. Our principal executive offices are located at 4800 Montgomery Lane, Suite&#160;220, Bethesda, MD 20814. Our telephone number is (301) 500-1556. Our website address is http://www.gaintherapeutics.com. Information contained on or accessible through our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Implications of Being an Emerging Growth Company and Smaller Reporting Company</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are an &#8220;emerging growth company&#8221;, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. Some of these exemptions include: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we are required to report only two&#160;years of audited financial statements and only two&#160;years of related selected financial data and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations disclosure; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we are not required to engage an auditor to report on our internal control over financial reporting pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we are permitted to take advantage of extended transition periods for complying with new or revised accounting standards which allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we are not required to submit certain executive compensation matters to stockholder advisory votes, such as &#8220;say-on-pay,&#8221; &#8220;say-on-frequency,&#8221; and &#8220;say-on-golden parachutes;&#8221; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">we are not required to comply with certain disclosure requirements related to executive compensation, such as the requirement to disclose the correlation between executive compensation and performance and the requirement to present a comparison of our Chief Executive Officer&#8217;s compensation to our median employee compensation. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We will remain an emerging growth company until the earlier of (1)&#160;December&#160;31, 2026, (2)&#160;the last day of the fiscal year in which we have total annual gross revenue of at least $1.07&#160;billion, (3)&#160;the last day of the fiscal year in which the market value of our common stock that is held by non-affiliates exceeds $700&#160;million as of the prior June&#160;30</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;">, and (4)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt during the prior three-year period. We have chosen to take advantage of some but not all of these available exemptions. We have elected to adopt the reduced requirements with respect to our financial statements and the related selected financial data and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure. We have also elected to take advantage of the extended transition periods for complying with certain new or revised accounting standards. As a result, the information that we provide to stockholders may be different than the information you may receive from other public companies in which you hold equity. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our shares held by non-affiliates plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700&#160;million and our annual revenue was less than $100&#160;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&#160;the market value of our shares held by non-affiliates is less than $250&#160;million or (ii)&#160;our annual revenue was less than $100&#160;million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700&#160;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal&#160;years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </font>
          </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">The Securities We May Offer</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We may offer shares of our common stock and preferred stock, various series of debt securities and warrants to purchase any of such securities, up to a total aggregate offering price of $100,000,000, from time to time in one or more offerings under this prospectus, together with any applicable prospectus supplement and any related free writing prospectus, at prices and on terms to be determined by market conditions at the time of the relevant offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">designation or classification; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">aggregate principal amount or aggregate offering price; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">maturity; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">original issue discount; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">rates and times of payment of interest or dividends; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">redemption, conversion, exchange or sinking fund terms; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">ranking; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">restrictive covenants; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">voting or other rights; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">conversion or exchange prices or rates and any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">important U.S. federal income tax considerations. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We may sell the securities directly to investors or through underwriters, dealers or agents. We, and our underwriters or agents, reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in the applicable prospectus supplement: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the names of those underwriters or agents; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">applicable fees, discounts and commissions to be paid to them; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">details regarding over-allotment options, if any; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <!--blacklining:none;-->
            <font style="letter-spacing:0.2pt;">the estimated net proceeds to us. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Common Stock</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;We may issue shares of our common stock from time to time. Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders and does not have cumulative voting rights. Subject to preferences that may apply to any outstanding preferred stock, holders of our common stock are entitled to receive ratably any dividends that our board of directors may declare out of funds legally available for that purpose. In the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preference of any outstanding preferred stock. Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future. In this prospectus, we have summarized certain general features of our common stock under the heading &#8220;Description of Capital Stock&#8201;&#8212;&#8201;Common Stock.&#8221; We urge you, however, to read the applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to any common stock being offered. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Preferred Stock</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;We may issue shares of our preferred stock from time to time, in one or more series. Under our certificate of incorporation, our board of directors has the authority, without further action by our stockholders (unless such stockholder action is required by applicable law or the rules of any stock exchange or market on which our securities are then traded), to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the number, rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences and sinking fund terms, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. Any convertible preferred stock we may issue will be convertible into our common stock or exchangeable for our other securities. Conversion may be mandatory or at the holder&#8217;s option and would be at prescribed conversion rates. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">If we sell any series of preferred stock under this prospectus, we will fix the designations, voting powers, preferences and rights of such series of preferred stock, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock that we are offering before the issuance of the related series of preferred stock. In this prospectus, we have summarized certain general features of the preferred stock under the heading &#8220;Description of Capital Stock&#8201;&#8212;&#8201;Preferred Stock.&#8221; We urge you, however, to read the applicable prospectus supplement </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:17.5pt;min-height:660pt;margin-left:12pt;width:456pt;">
          <div style="width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">(and any free writing prospectus that we may authorize to be provided to you) related to the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Debt Securities</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;From time to time, we may issue debt securities in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be subordinate and junior in right of payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible debt securities will be convertible into or exchangeable for our common stock or other securities. Conversion may be mandatory or at the holder&#8217;s option and would be at prescribed conversion rates. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Any debt securities issued under this prospectus will be issued under one or more documents called indentures, which are contracts between us and a national banking association or other eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities under the heading &#8220;Description of Debt Securities.&#8221; We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as well as the complete indenture(s) and any supplemental indentures that contain the terms of the debt securities. We have filed a form of indenture as an exhibit to the registration statement of which this prospectus is a part.&#8199;&#8199;We will file as exhibits to the registration statement of which this prospectus is a part, or will be incorporated by reference from reports that we file with the SEC, supplemental indentures and forms of debt securities containing the terms of the debt securities being offered. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Warrants</font><font style="font-style:italic;letter-spacing:0.2pt;">.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We may issue warrants for the purchase of common stock, preferred stock or debt securities, in one or more series, from time to time. We may issue warrants independently or in combination with common stock, preferred stock or debt securities. In this prospectus, we have summarized certain general features of the warrants under the heading &#8220;Description of Warrants.&#8221; We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants. We have filed forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants that we may offer as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will be incorporated by reference from reports that we file with the SEC, the form of warrant or the warrant agreement and warrant certificate, as applicable, that contain the terms of the particular series of warrants we are offering, and any supplemental agreements, before the issuance of such warrants. </font>
          </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Any warrants issued under this prospectus may be evidenced by warrant certificates. Warrants may be issued under a warrant agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of warrants being offered.</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:476pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in our <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1819411/000155837022004363/ganx-20211231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2021</a> and in our most recent Quarterly Report on Form 10-Q, as updated by our subsequent filings, which are incorporated by reference into this prospectus, before deciding whether to purchase any of the securities being registered pursuant to the registration statement of which this prospectus is a part. Each of the risk factors could adversely affect our business, results of operations, financial condition and cash flows, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our business operations. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus and the documents incorporated by reference contain forward-looking statements. These are based on our management&#8217;s current beliefs, expectations and assumptions about future events, conditions and results and on information currently available to us. Discussions containing these forward-looking statements may be found, among other places, in the sections titled &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; incorporated by reference from our most recent Annual Report on Form 10-K, as well as any amendments thereto, filed with the SEC. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In some cases, you can identify forward-looking statements by terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expects,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative or plural of those terms, and similar expressions intended to identify statements about the future, although not all forward-looking statements contain these words. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any statements in this prospectus, or incorporated herein, about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Within the meaning of Section&#160;27A of the Securities Act and Section&#160;21E of the Exchange Act, these forward-looking statements include statements regarding: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the impact of the COVID-19 pandemic and its effects on our operations, access to capital, research and development and clinical trials and potential disruption in the operations and business of third-party manufacturers, contract research organizations other service providers, and collaborators with whom we conduct business; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and our research and development programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the success of our efforts to expand our pipeline of product candidates and develop marketable products through the use of our Site-Directed Enzyme Enhancement Therapy, or SEE-Tx</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> platform; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations regarding collaborations and other agreements with third parties and their potential benefits; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to obtain regulatory approval of our current and future product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our reliance upon intellectual property licensed from third parties, including the license to use the technology under our SEE-Tx</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;"> platform; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations regarding the potential market size and the rate and degree of market acceptance of such product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to fund our working capital requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">developments or disputes concerning our intellectual property or other proprietary rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to maintain and establish collaborations or obtain additional funding; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our expectations regarding government and third-party payor coverage and reimbursement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our ability to compete in the markets we serve; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the impact of government laws and regulations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">developments or projections relating to our competitors or our industry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">developments relating to our competitors and our industry; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the factors that may impact our financial results. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:464pt;margin-left:69.66pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You should refer to the &#8220;Risk Factors&#8221; section contained in this prospectus and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus, for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Given these risks, uncertainties and other factors, many of which are beyond our control, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate, and you should not place undue reliance on these forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to revise any forward-looking statements to reflect events or developments occurring after the date of this prospectus, even if new information becomes available in the future. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:476pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will retain broad discretion over the use of the net proceeds from the sale of the securities offered hereby. Except as described in any applicable prospectus supplement or in any free writing prospectuses that we may authorize to be provided to you in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered hereby, if any, to fund research and development, acquire or invest in businesses, products or technologies that are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus, and for working capital and general corporate purposes. We will set forth in the applicable prospectus supplement or free writing prospectus our intended use for the net proceeds received from the sale of any securities sold pursuant to the prospectus supplement or free writing prospectus. Pending the use of net proceeds, we intend to invest the net proceeds in short-term, investment-grade, interest-bearing obligations, certificates of deposit or direct or guaranteed obligations of the United States. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDOCS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF CAPITAL STOCK</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">The following description of our capital stock and provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries. You should also refer to the amended and restated certificate of incorporation and the amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus is part.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our certificate of incorporation authorizes us to issue up to 50,000,000 shares of common stock, $0.0001 par value per share, and 10,000,000 shares of preferred stock, $0.0001 par value per share, all of which shares of preferred stock are undesignated. Our board of directors may establish the rights and preferences of the preferred stock from time to time. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Voting Rights</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Holders of shares of our common stock are entitled to one vote for each share held of record on all matters on which stockholders are entitled to vote generally, including the election or removal of directors elected by our stockholders generally. The holders of our common stock do not have cumulative voting rights in the election of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Dividends and Liquidation Rights</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Holders of shares of our common stock are entitled to receive dividends when, as and if declared by our board of directors out of funds legally available therefor, subject to any statutory or contractual restrictions on the payment of dividends and to any restrictions on the payment of dividends imposed by the terms of any outstanding preferred stock. Upon our liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of shares of our common stock will be entitled to receive our remaining assets available for distribution on a pro&#160;rata basis. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Rights and Preferences</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;All shares of our common stock that will be outstanding are fully paid and non-assessable. The common stock will not be subject to further calls or assessments by us. Holders of shares of our common stock do not have preemptive, subscription, redemption or conversion rights. There will be no redemption or sinking fund provisions applicable to the common stock. The rights powers, preferences and privileges of our common stock will be subject to those of the holders of any shares of our preferred stock or any other series or class of stock we may authorize and issue in the future. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Transfer Agent and Registrar</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;The transfer agent and registrar for our common stock is Philadelphia Stock Transfer, Inc., 2320 Haverford Rd., Suite 230, Ardmore, Pennsylvania 19003. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors may, without further action by our stockholders, fix the rights, preferences, privileges and restrictions of up to an aggregate of 10,000,000 shares of preferred stock in one or more series and authorize their issuance. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of our common stock. The issuance of our preferred stock could adversely affect the voting power of holders of our common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change of control or other corporate action. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors will fix the designations, voting powers, preferences and rights of each series, as well as the qualifications, limitations or restrictions thereof, of the preferred stock of each series that we offer under this prospectus and applicable prospectus supplements in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of that series of preferred stock. This description will include: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the title and stated value; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the number of shares we are offering; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the liquidation preference per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the purchase price per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the dividend rate per share, dividend period and payment dates and method of calculation for dividends; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our right, if any, to defer payment of dividends and the maximum length of any such deferral period; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the procedures for any auction and remarketing, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the provisions for a sinking fund, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any listing of the preferred stock on any securities exchange or market; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the preferred stock will be convertible into our common stock or other securities of ours, including depositary shares and warrants, and, if applicable, the conversion period, the conversion price, or how it will be calculated, and under what circumstances it may be adjusted; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange period, the exchange price, or how it will be calculated, and under what circumstances it may be adjusted; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">voting rights, if any, of the preferred stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">preemption rights, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">restrictions on transfer, sale or other assignment, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether interests in the preferred stock will be represented by depositary shares; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a discussion of any material or special U.S. federal income tax considerations applicable to the preferred stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any limitations on issuances of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock being issued as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other specific terms, rights, preferences, privileges, qualifications or restrictions of the preferred stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anti-Takeover Provisions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Section&#160;203 of the Delaware General Corporation Law</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are subject to Section&#160;203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three&#160;years after the date that such stockholder became an interested stockholder, with the following exceptions: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, those shares owned (i)&#160;by persons who are directors and also officers and (ii)&#160;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In general, Section&#160;203 defines a &#8220;business combination&#8221; to include the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any merger or consolidation involving the corporation and the interested stockholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In general, Section&#160;203 defines an &#8220;interested stockholder&#8221; as an entity or person who, together with the entity or person&#8217;s affiliates and associates, beneficially owns, or is an affiliate or associate of the corporation and within three&#160;years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anti-Takeover Effects of Certain Provisions of our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the voting power of our shares of common stock outstanding will be able to elect all of our directors. The directors may be removed by the stockholders only for cause upon the vote of holders of 66-2/3% of the shares then entitled to vote at an election of directors. Furthermore, the authorized number of directors may be changed only by resolution of our board of directors, and vacancies and newly created directorships on our board of directors may, except as otherwise required by law or determined by our board, only be filled by a majority vote of the directors then serving on the board, even though less than a quorum. Our certificate of incorporation and bylaws provide that all stockholder actions must be effected at a duly called meeting of stockholders and not by a consent in writing. A special meeting of stockholders may be called at any time only by or at the direction of the board of directors or the chairman of the board of directors. Our bylaws also provide that stockholders seeking to present proposals before a meeting of stockholders to nominate candidates for election as directors at a meeting of stockholders must provide timely advance notice in writing, and will specify requirements as to the form and content of a stockholder&#8217;s notice. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our certificate of incorporation further provides that the affirmative vote of the holders of at least 66&#160;2/3% of the votes which all our stockholders would be entitled to cast in any election of directors will be required to amend certain provisions of our certificate of incorporation, including provisions relating to the size of the board, removal of directors, special meetings of stockholders, actions by written consent and cumulative voting. The affirmative vote of holders of at least 66 2/3% of the voting power of all of the then outstanding shares of voting stock, voting as a single class, is required to amend or repeal our bylaws, although our bylaws may be amended by a simple majority vote of our whole board of directors. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The foregoing provisions will make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of the Company by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:108pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change the control of our company. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These provisions are also designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy rights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes in control of the Company or our management. As a consequence, these provisions also may inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Choice of Forum</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will, to the fullest extent permitted by applicable law, be the sole and exclusive forum for: (1)&#160;any derivative action or proceeding brought on our behalf; (2)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees or stockholders to us or our stockholders; (3)&#160;any action asserting a claim against us, any director or our officers and employees arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our amended and restated bylaws, or as to which the Delaware General Corporation Law confers exclusive jurisdiction on the Court of Chancery; or (4)&#160;any action asserting a claim against us, any director or our officers or employees that is governed by the internal affairs doctrine; provided that the exclusive forum provisions will not apply to suits brought to enforce any liability or duty created by the Exchange Act, or to any claim for which the federal courts have exclusive jurisdiction. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our certificate of incorporation further provides that, unless we consent in writing to the selections of an alternative forum, the federal district courts are the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, subject to a final adjudication in the State of Delaware of the enforceability of such exclusive forum provision. We note that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Although we believe the provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against our directors and officers. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transfer Agent and Registrar</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The transfer agent and registrar for our common stock is Philadelphia Stock Transfer, Inc., 2320&#160;Haverford Rd., Suite 230, Ardmore, Pennsylvania 19003. The transfer agent for any series of preferred stock that we may offer under this prospectus will be named and described in the prospectus supplement for that series. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Listing on The Nasdaq Global Market</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our common stock is listed on Nasdaq under the symbol &#8220;GANX.&#8221; </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tDODS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF DEBT SECURITIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will issue the debt securities under the indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act. We have filed the form of indenture as an exhibit to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will be incorporated by reference from reports that we file with the SEC, supplemental indentures and forms of debt securities containing the terms of the debt securities being offered. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following summary of material provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The indenture does not limit the amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against changes in our operations, financial condition or transactions involving us. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may issue the debt securities issued under the indenture as &#8220;discount securities,&#8221; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#8220;original issue discount,&#8221; or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more detail in any applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the title of the series of debt securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any limit upon the aggregate principal amount that may be issued; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the maturity date or dates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the form of the debt securities of the series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the applicability of any guarantees; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any subordination; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if the price (expressed as a&#160;percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into another security or the method by which any such portion shall be determined; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.29pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.29pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our right, if any, to defer payment of interest and the maximum length of any such deferral period; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#8217;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or securities; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders&#8217; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">additions to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation, merger or sale covenant; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">additions to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">additions to or changes in the provisions relating to satisfaction and discharge of the indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether interest will be payable in cash or additional debt securities at our or the holders&#8217; option and the terms and conditions upon which the election may be made; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any and principal amounts of the debt securities of the series to any holder that is not a &#8220;United States person&#8221; for federal tax purposes; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any restrictions on transfer, sale or assignment of the debt securities of the series; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Conversion or Exchange Rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Consolidation, Merger or Sale</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Events of Default under the Indenture</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect to any series of debt securities that we may issue: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become due and payable, and such default continues for a period of 90&#160;days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of interest for this purpose; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90&#160;days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if specified events of bankruptcy, insolvency or reorganization occur. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the terms of the indenture, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the direction so given by the holder is not in conflict with any law or the applicable indenture; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A holder of the debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the holder has given written notice to the trustee of a continuing event of default with respect to that series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred by the trustee in compliance with the request; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90&#160;days after the notice, request and offer. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will periodically file statements with the trustee regarding our compliance with specified covenants in the indenture. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Modification of Indenture; Waiver</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We and the trustee may change an indenture without the consent of any holders with respect to specific matters: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to comply with the provisions described above under &#8220;Description of Debt Securities&#8201;&#8212;&#8201;Consolidation, Merger or Sale;&#8221; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to provide for uncertificated debt securities in addition to or in place of certificated debt securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred upon us in the indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to make any change that does not adversely affect the interests of any holder of debt securities of any series in any material respect; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above under &#8220;Description of Debt Securities&#8201;&#8212;&#8201;General&#8221; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">extending the fixed maturity of any debt securities of any series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption of any series of any debt securities; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">reducing the&#160;percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Discharge</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">provide for payment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">register the transfer or exchange of debt securities of the series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">replace stolen, lost or mutilated debt securities of the series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">pay principal of and premium and interest on any debt securities of the series; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">maintain paying agencies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">hold monies for payment in trust; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">recover excess money held by the trustee; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">compensate and indemnify the trustee; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">appoint any successor trustee. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Form, Exchange and Transfer</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the applicable prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we elect to redeem the debt securities of any series, we will not be required to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15&#160;days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Information Concerning the Trustee</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Payment and Paying Agents</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two&#160;years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:572pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Governing Law</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The indenture and the debt securities will be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture Act of 1939 is applicable. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a><a name="tDOW">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF WARRANTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following description, together with the additional information we may include in any applicable prospectus supplement and in any related free writing prospectus that we may authorize to be distributed to you, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or more series. Warrants may be offered independently or in combination with common stock, preferred stock or debt securities offered by any prospectus supplement. While the terms we have summarized below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement. The following description of warrants will apply to the warrants offered by this prospectus unless we provide otherwise in the applicable prospectus supplement. The applicable prospectus supplement for a particular series of warrants may specify different or additional terms. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have filed forms of the warrant agreements and forms of warrant certificates listing the terms of the warrants that may be offered as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant or the warrant agreement and warrant certificate, as applicable, that contain the terms of the particular series of warrants we are offering, as well as any supplemental agreements, before the issuance of such warrants. The following summaries of material terms and provisions of the warrants are subject to, and qualified in their entirety by reference to, all the provisions of the&#8199;&#8199;form of warrant or the warrant agreement and warrant certificate, as applicable, and any supplemental agreements applicable to a particular series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplement related to the particular series of warrants that we may offer under this prospectus, as well as any related free writing prospectus, and the complete form of warrant or the warrant agreement and warrant certificate, as applicable, and any supplemental agreements, that list the terms of the warrants. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the applicable prospectus supplement, we will describe the terms of the series of warrants being offered, including, to the extent applicable: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the offering price and aggregate number of warrants offered; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the currency for which the warrants may be purchased; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable on exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased on such exercise; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable on the exercise of one warrant and the price at which these shares may be purchased on such exercise; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the terms of any rights to redeem or call the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any provisions for changes to or adjustments in the exercise price or number of securities issuable on exercise of the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the dates on which the right to exercise the warrants will commence and expire; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the manner in which the warrant agreements and warrants may be modified; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">a discussion of material or special U.S. federal income tax considerations of holding or exercising the warrants; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC3">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:126pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the terms of the securities issuable on exercise of the warrants; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any other specific terms, preferences, rights or limitations of or restrictions on the warrants. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable on such exercise, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or payments on our liquidation, dissolution or winding up or to exercise voting rights, if any; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable on exercise or to enforce covenants in the applicable indenture. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Exercise of Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement. The warrants may be exercised as listed in the prospectus supplement relating to the warrants offered. Unless we otherwise specify in the applicable prospectus supplement, warrants may be exercised at any time up to the specified time on the expiration date that we list in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On receipt of payment and the warrant or warrant certificate, as applicable, properly completed and duly executed at the corporate trust office of the warrant agent, if any, or any other office, including ours, indicated in the prospectus supplement, we will, as soon as practicable, issue and deliver the securities purchasable on such exercise. If less than all of the warrants (or the warrants represented by such warrant certificate) are exercised, a new warrant or a new warrant certificate, as applicable, will be issued for the remaining warrants. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Governing Law</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless we provide otherwise in the applicable prospectus supplement, the warrants and warrant agreements will be governed by and construed in accordance with the laws of the State of New York. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Enforceability of Rights by Holders of Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each warrant agent, if any, will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand on us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable on exercise of, its warrants. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tLOOS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL OWNERSHIP OF SECURITIES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee or depositary maintain for this purpose as the &#8220;holders&#8221; of those securities. These persons are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#8220;indirect holders&#8221; of those securities. As we discuss below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Book-Entry Holders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#8217;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Only the person in whose name a security is registered is recognized as the holder of that security. Global securities will be registered in the name of the depositary or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a result, investors in a global security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#8217;s book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Street Name Holders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may terminate a global security or issue securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in &#8220;street name.&#8221; Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not holders, of those securities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Legal Holders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">obligation to comply with a particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the holders, and not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Special Considerations for Indirect Holders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If you hold securities through a bank, broker or other financial institution, either in book-entry form because the securities are represented by one or more global securities or in street name, you should check with your own institution to find out: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">how it handles securities payments and notices; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether it imposes fees or charges; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">how it would handle a request for the holders&#8217; consent, if ever required; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:3.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if the securities are in book-entry form, how the depositary&#8217;s rules and procedures will affect these matters. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:10.12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Global Securities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each security issued in book-entry form will be represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, New York, known as DTC, will be the depositary for all securities issued in book-entry form. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under &#8220;&#8212; Special Situations When a Global Security Will Be Terminated.&#8221; As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If the prospectus supplement for a particular security indicates that the security will be issued as a global security, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Special Considerations for Global Securities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As an indirect holder, an investor&#8217;s rights relating to a global security will be governed by the account rules of the investor&#8217;s financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If securities are issued only as global securities, an investor should be aware of the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:74pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">an investor may not be able to pledge his or her interest in the global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the depositary&#8217;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&#8217;s interest in the global security; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">we and any applicable trustee have no responsibility for any aspect of the depositary&#8217;s actions or for its records of ownership interests in the global security, nor will we or any applicable trustee supervise the depositary in any way; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">financial institutions that participate in the depositary&#8217;s book-entry system, and through which an investor holds its interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the securities. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Special Situations When a Global Security Will Be Terminated</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In a few special situations described below, a global security will terminate and interests in it will be exchanged for physical certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in securities transferred to their own names, so that they will be direct holders. We have described the rights of holders and street name investors above. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unless we provide otherwise in the applicable prospectus supplement, the global security will terminate when the following special situations occur: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90&#160;days; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if we notify any applicable trustee that we wish to terminate that global security; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tPOD">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PLAN OF DISTRIBUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">at a fixed price or prices, which may be changed; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">at market prices prevailing at the time of sale; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">at prices related to such prevailing market prices; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">at negotiated prices. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may also sell equity securities covered by this registration statement in an &#8220;at the market offering&#8221; as defined in Rule&#160;415 under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">on or through the facilities of Nasdaq or any other securities exchange or quotation or trading service on which such securities may be listed, quoted or traded at the time of sale; and/or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">other than on Nasdaq or such other securities exchanges or quotation or trading services. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Such at the market offerings, if any, may be conducted by underwriters acting as principal or agent. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the name or names of any underwriters, dealers or agents, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">the purchase price of the securities and the proceeds we will receive from the sale; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any over-allotment options under which underwriters may purchase additional securities from us; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any agency fees or underwriting discounts and other items constituting agents&#8217; or underwriters&#8217; compensation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any public offering price; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.21pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.21pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any discounts or concessions allowed or reallowed or paid to dealers; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">any securities exchange or market on which the securities may be listed. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities, and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:236pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may provide agents and underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All securities we offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids. Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. These transactions may be effected on any exchange or over-the-counter market or otherwise. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any underwriters who are qualified market makers on Nasdaq may engage in passive market making transactions in the securities on Nasdaq in accordance with Rule&#160;103 of Regulation&#160;M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a><a name="tEXP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:468pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Cooley LLP, Reston, Virginia, will pass upon the validity of the securities offered by this prospectus, and any supplement thereto, unless otherwise indicated in the applicable prospectus supplement. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The consolidated financial statements of Gain Therapeutics, Inc. appearing in Gain Therapeutics,&#160;Inc.&#8217;s <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1819411/000155837022004363/ganx-20211231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2021</a> have been audited by Ernst &amp; Young AG, independent registered public accounting firm, as set forth in their report, which is incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:488pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus is part of the registration statement on Form S-3 we filed with the SEC under the Securities Act and does not contain all of the information set forth in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement or other document. Because we are subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#8217;s website at http://www.sec.gov. We maintain a website at www.gaintherapeutics.com. Information contained in or accessible through our website does not constitute a part of this prospectus. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tIOCI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:234pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SEC allows us to &#8220;incorporate by reference&#8221; information into this prospectus, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is 001-38085. The documents incorporated by reference into this prospectus contain important information that you should read about us. </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following documents are incorporated by reference into this document: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;">our <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1819411/000155837022004363/ganx-20211231x10k.htm">Annual Report on Form 10-K for the year ended December&#160;31, 2021, filed with the SEC on March&#160;25, 2022</a>, as amended by Amendment No. 1 on <a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1819411/000110465922054769/tm2214164d1_10ka.htm">May&#160;2, 2022;</a> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <!--blacklining:none;-->
          <font style="letter-spacing:0.2pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/1819411/000155837022008968/ganx-20220331x10q.htm">our Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2022, filed with the SEC on May&#160;16, 2022; and</a> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;letter-spacing:0.2pt;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;letter-spacing:0.2pt;">
          <!--blacklining:none;-->
          <a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1819411/000114036121008904/nt10015006x14_8a12b.htm">the description of our common stock contained in our Registration Statement on Form 8-A, filed with the SEC on March&#160;17, 2021, including any amendments or reports filed for the purposes of updating this description.</a><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We also incorporate by reference into this prospectus all documents (other than current reports furnished under Item&#160;2.02 or Item&#160;7.01 of Form 8-K and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act (301) after the date of the initial filing of the registration statement of which this prospectus forms a part and prior to effectiveness of the registration statement, or (ii)&#160;after the date of this prospectus but prior to the termination of the offering. These documents include periodic reports, such as Annual Reports on Form&#160;10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as proxy statements. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">You can request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Gain Therapeutics, Inc. </font>
          <br >
          <font style="letter-spacing:0.2pt;">Attn: Corporate Secretary </font>
          <br >
          <font style="letter-spacing:0.2pt;">4800 Montgomery Lane, Suite&#160;220, </font>
          <br >
          <font style="letter-spacing:0.2pt;">Bethesda, MD 20814 </font>
          <br >
          <font style="letter-spacing:0.2pt;">(301) 500-1556</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:14pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="position:relative;margin-top:72.35pt; text-align:center; width:456pt;">
          <img src="lg_gaintherapeutics-4c.jpg" alt="[MISSING IMAGE: lg_gaintherapeutics-4c.jpg]" height="93" width="196" >
        </div>
        <div style="margin-top:74.35pt; text-align:center; width:456pt; line-height:16pt;">
          <font style="letter-spacing:-0.28pt;">SHARES OF COMMON STOCK</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:15.5pt;">
          <font style="letter-spacing:-0.28pt;">PRE-FUNDED WARRANTS TO PURCHASE UP TO &#8199;&#8199;&#8199;&#8199;&#8199;SHARES </font>
          <br >
          <font style="letter-spacing:-0.28pt;">OF COMMON STOCK</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:15.5pt;">
          <font style="letter-spacing:-0.28pt;">UP TO&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;SHARES OF COMMON STOCK ISSUABLE UPON</font>
          <br >
          <font style="letter-spacing:-0.28pt;">EXERCISE OF THE PRE-FUNDED WARRANTS</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:15.5pt;">
          <font style="text-transform:uppercase;letter-spacing:-0.28pt;">Underwriter Warrants to Purchase up to &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; Shares of Common Stock</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:15.5pt;">
          <font style="letter-spacing:-0.28pt;">UP TO &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THE UNDERWRITER WARRANTS</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:24pt; text-align:center; width:456pt; line-height:14pt;font-size:12pt;">
          <font style="letter-spacing:-0.24pt;">PRELIMINARY PROSPECTUS SUPPLEMENT</font><font style="font-weight:normal;letter-spacing:0.24pt;"> </font>
        </div>
        <div style="margin-top:24pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">Sole Bookrunner</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:19.14pt; text-align:center; width:456pt; line-height:20pt;font-size:18pt;">
          <font style="letter-spacing:-0.36pt;">Titan Partners Group</font><font style="font-weight:normal;letter-spacing:0.36pt;"> </font>
        </div>
        <div style="margin-top:2pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;font-weight:normal;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">a division of American Capital Partners</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:54.21pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, 2024</font>
        </div>
        <div style="margin-top:98.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 98.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:2.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 2.5pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>lg_gaintherapeutics-4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_gaintherapeutics-4c.jpg
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M%!04%!04%!04%!04%!04%!04%!3_P  1" "2 3$# 1$  A$! Q$!_\0 Q@
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MX2^LARGH[@VA;3BFU>JDBE I-8&[RYKAJIE=:/,<R2I,='Y+<%>>M%/L??\
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M;]KNEOO5OC7:TR42[=+0'8TEH\2%H5RC[1!V@[#56TTZ,U,9*2JL#EU\/04
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MP(MK@1;9!;#,*&TB/&:3N2TTD)2D=P"J9NKJ;B,5%)+!')KX>@H H H H H
MH H H H H#@WF[0[#:9MZN"^KA0&7)#ZN7@;25$#G)PP YZ^I5=#Q.:A%R>"
M/GIF:]S<TW^XYAN!)EW%];ZQCB$!1\% Z$) 2.@5<QCRJAB+MQW).3WFPT2R
M0,YY]@L26^.TVW\X7#$8I4AE0X&SS\:RE)'L<:YWI\L25D;/FW5V+:QE]J7)
M(1)MV>H;?@O@6^Z%(_?$@J8</=2%()]JD5PRT_M)^J6:-7%P9-_5U-*(NK17
M.GZ:Y#@R9+G67>W#S"Y<1Q4IQD#A<//QH*5$^RQYJJ;T.61L,E?\VTGO6QC$
MKB3@H H H"&=?$8ZLYA/MHWR5FK6QT(R&?\ 7EW>!B\M-_WCM'QV-\*FNLL&
M1+76N)]&JI3=!0$.=H!&.K-_/Q7Y(U5K8Z$9#4/7EW>!A+ PA=^M:'$!;:I<
M<*0L!25 NIQ!!V$&NLL"';ZEQ')K=H:O+#DC-N4V2YEQQ1<FP4#%4(J.)4D#
M>SC^!W*C6;W-L>):Y[)>7]<.GP_P(KJJEE.-/1_5VX:<3_,)W62\IREXRH@V
MK86=G7,@G?[).Y7=P-1[MKGXECD\X[+H^DM&UW2WWJWQKK:I")=NEH#L>0T<
M4J2?M$;B#M!V';58TTZ,U<)J2JMJ9RZ^'H* C+M,HXM35G^@1OW=6>7Z#*ZG
MZW<A.]54DJR_L*IS:$*S5KE3)$ESRCSJW%=U:B3]NK=&+DZNHS.SS;VY.J%N
M=<3Q>:,2GTX[@KJBV#WN.N&8?T%CIJK?7NJ6?56:T* * * 2>>.T;E_+TQVU
MY<B&^3&3P.R@X&H:5 [0E0"BYAT #F)J5#+M[7L*>_J<(.D5S/\ (PW_ +2Y
MG_L*#^&]^-7;]LNTA?VT_P!*#_VES/\ V%!_#>_&I^V7:/[:?Z4 [4N9L1C8
M8.'+X;W^VG[9=H_MI_I1^G_M-F#_  ]#_EG?]E?/VJ[3[_;2_2C9Z7ZYW3/N
M:F\O3;1'ALN,.O!YEQ:U!30! P4,,#7.[848UJ2\IGY7KG*U0=U1"Y"@)_[3
M><3%M4+),-S!^X$3+B$G:(S2O>D'W;@XOO.FIF6AMYBCU2_2*MK?M9+O5=%3
MS-EC=GK)8RSDE-VDM\-TOY3+<)'A)C)!#">^"7/OJK<Q.LJ=AK-.L<EOF>,O
M9# SCEJ+G#+-SRY+P#<YE2&W",>K>3X3:_O5A*JXPERNI.O6E<@XO>0#/MLJ
MVS9-NFMEJ9$=6Q(:.]+C:BE0[Q%7"=3#RBXMIXH:?9\S@<KYU1:I3G!:K^$Q
M' 3X*9()+"^^HEO[ZH]^'-&O866G7_+N4>$O9%CU6&L"@"@"@(CUW1CJK?S[
M:-\E:JUL=",?J'KR[O QF6V_[PVC9^6QOA4UUE@R):ZUQ1]#ZI3=A0$2Z]M\
M6JU]/Q7Y*U5K8Z$8_4/7EW>!B,OM?GZU_'(_PJ:ZRP9#M]2XGT/<;0ZA33J0
MMM8*5H4 4J21@00=X-4IO"4-:=#UY;6_FO*;)7EY1+DV C$JAD[U)'*S^T]S
MNL;-ZNQXF8SV1Y/KAT^'^!&]5T5**89ND>J]QTZN'F<OCEY5EK!F0P<5,J.S
MKF<=RAZY.Y0Z<".%VTIKWECD\X[+H]L667;+G O,"/=+7(1*M\I <CR&SBE2
M3]HC<0=H.PU6--.C-;":DJK:F<NOAZ([[2;?%J4L_P!!C?NZL\OT&4U/UNY"
M@ZKHJ051>F%5!MB()L-<69(C+!"V75MJQYT*(/VJMDS$RV-H8^@$E$+4RW(<
M/");,F.#R<1:4L#OE%<+ZK L=-E2^O?4L>JPUX4 4 J]?LTRLNY'5$@.%J;>
M71"ZQ)P4ECA*W2#T@!'WU2+$:RX%7J5YV[5%C+81]U715F9&H=5T4%0ZKHH*
MAU7105#JNB@J-OLY1%N:BAU(/"Q!D.*[A*$?;54;,/Z"VTM5O=S*ZJM-8?C*
ME1X,5^;+<#46,VMY]U7BI;;25*4>@ 5]2J?)-)59!^=LQ2,XYIN689 ($MT^
M;MJ_>V$>"TCO) QZ=M6\(\JH8;,7G=N.3WG)T\R>O.>;[;8^$^:..=;.6/6Q
M6O"<./(2/!'217RY/EC4]96SYMQ1_'@76VVVRVAEI(0TVD(0A(P2E*1@  .0
M"J@VZ5#VH?25.T;DP6K,S&:8C>$*])X9/"-B9C( ./-QHP/20JK'+SJJ=AE]
M4L\L^=82\1+(2MI:7&R4.((4A:3@0H;001S5**:I=&FV;4YTR=;KTI0,W@\W
MN"1ZV4S@E>P;N+8L#F4*J+D.65#;92_YMM2W[^)K*YDL* * BW7)OBU1OQP]
M='^3-5:6.A&-U#UY=W@8[+K6&8+2</RR/\*FNLL&1+76N*/H'5,;T* B_75O
MBU2OA^+?)6JM+'0C':CZ\N[P,58&A\^VO9^5L?")KK+!D*WUKB?06J8WQX6A
M#B%(6D*0H%*DJ&((.P@@T!+6LNBBK M_-64XY785$N3H#8Q,0G:5H'*UT>L]
MSNL+-ZNQXF8S^0</KAT[UV?X$?U0YJEE(,K2C52X:>SO-)7'+RO*7C*A@XJ:
M6=G6LX[ KV2=RATX$<+MI37O+')YUV'1[8E@VNZ6^]6^/=;7(1*M\I <8?;.
M*5)/V00=A!V@[#58TTZ,UT)J:33JF2=VC$<6HZS_ $&-^[JQR_09;5/6[D*7
MJAS5)*DNG"J@VY*^JMA58\_WR+P\++\A4QCF+<KWT8= *BGO58VI5BC)YVWR
M7I+WU_$S^7[F_E^^6Z]QQB[;Y#4@)W<0;4"4]Q0V5TDJJA'M7.2:DMS+M@3H
MUS@QKC"6'8<MI#[#@]<VXD*2?4-4[5'0WL9*236#.17P]!0'#GVFUW5*$72#
M'FH;)4VF2TAX))V$@+!PKZFU@>)0C+%)G!_0_*7]@6[^IL?B5ZYY=IS\BW^E
M?@@_0_*7]@6[^IL?B4YY=H\BW^E?@@_0_*7]@6[^IL?B4YY=H\BW^E?@C$:M
M0<JY:R'=)D>S6]F=)0(4-:(K"5AV0>$E)"004HXE##FKK:<I26T@YZ-NW9;4
M57#!$D]55D9"I0/9FLQ#M^ORT[ EF"RKNDNN#[#=0LR\$:+1X=4NXH:H1HA.
M]H3-IM&66LMQ',)UZ)#^!VIB-$%?<XU8)Z1Q5*R\*NO84VJ7^2WR+&7@2UU1
MJP,I4IOLZY0^;+%*S5*;PEW974Q"1M3$95M(]VL'\$5 S$ZNAJ=*L<L'-XR\
M!V5$+L* R>I.4T9SR?<+.E(5-"?.+>3R26<5(P/)Q;4'H572W/EE4B9NQYMI
MQW[N)$JF%H44+24K22%).P@C>"*MC#CC[/.;#9LQO99EKP@WH8L8G8F6T"4]
MSC3BGI(347,0JJ]A<Z7F.6?(\)>)4=5YJ@H H"-];&^+4V^GVT?Y,U5I9Z$8
MS4?7EW>!D<OM?GZU?'(_PJ:ZRP9#M/ZUQ1>U4QOPH".=<&^+4Z]GXM\F:JTL
M=",9J/KR[O QMB:_/ELV?E;'PB:ZRP(=OK7$OBJ8WX4!X4E*TE"P%)4,%).T
M$'D- 3)K%HT;(M[-.56"JRJ)7/@-C$Q2=ZT ?O7./6>Y\6PLWJ['B9?/Y#D^
MN&&]=G^!)]5T5**08FENIMPR!/\ -I''*RU*6#,A@XJ;4=G6M8[E ;QN4.\1
MQNVE->\L<GG78='MBSD:Z385XSHS=+:\B3 EV^,['?0<0I!X^^#S@[17RPFH
MT/6I34KM5M32%GU717<K"W<*J3<"Z[0V4%38,/-T1OB=@_S2?AOZAQ6+:ST)
M62G[ZI&7G1T*O5[%8JXMVQD[=34XS%1]Z$ZA-L(1D>\NA"2HJL[ZS@,5G%3!
M)YR>)'?'L14*_;^Y&BTO.)?^J7=\A_5"-(% % % % % 2QK9GAO-=\1:+8YU
MEEM!4E+B3BAZ2=BUC#>E.'"D]TC8:L;%OE57BS(:EFU=GRQZ8^(K@P2< ,2=
MPJ25%2R-,<KG*.3;?;'D<$YT&7.&XA]_ E)Z4)X4=ZJJ[+FE4W.2L^5:2>.+
M->I24)*UD)0D$J43@ !O)-<B:1CJ-F1><<VS[N%$P@KS> D\D9HD(V<G%M6>
ME56MN/+&AA<Y?\ZZY;MW ZG+>79.9+[ L<08/37DME>&/ C>M9Z$I!4>Y7N4
MN55.-FV[LU%;RW+? BVN!&ML)'5PXC2&&&QR(;2$@>H*J&ZNIOH144DL$<FO
MAZ"@"@).ULR@,O9Q>FQF^&W7D&8S@,$AXGWY/X1XNXH596)UCP,=J5CR[M5A
M+;\Q>Q')$&4Q-B++4J,XAYEQ.]+C9"DD=PBN[VE9&3BZK%%LY2S"QFK+EOOK
M& \Z:!>;'K'D^"XCO*![U5,X\KH;S+WE=MJ:WG=5X) 4!(6LS7%J3>SSF/\
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M;;+:6F4);:0 E"$ )2E(V  #8!48O4DE1'M0^F3U%OSMBRS),3B-QF_S6($
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M"@"@"@"@"@"@"@"@"@"@"@"@"@"@"@"@"@$'_D3GK_'C_JR?^=4WSX_I,_\
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M+-=LSU=Q7Z1Z+X_!#DJ*71.EU_U-Q/=L?_GU.7H^W:9N?\]>WVE%U!-(*_M
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FL_ZFBT#^L;?T)Z[TOZ2_[;I^YC7C,8;R3IG7]O?CW%357&K/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>fc_pipeline-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_pipeline-4clr.jpg
M_]C_X0 817AI9@  24DJ  @              /_L !%$=6-K>0 !  0   !&
M  #_X0./:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B \
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 W+C(M8S P," W.2YD964S83<W,#,L(#(P,C(O,#@O
M,3@M,38Z-3 Z,S @(" @(" @("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@
M>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(B!X;7!-
M33I/<FEG:6YA;$1O8W5M96YT240](GAM<"YD:60Z868X.60V8V0M,#!A.2TT
M9&0W+6$T83,M965B8F,Y9C1C-C,S(B!X;7!-33I$;V-U;65N=$E$/2)X;7 N
M9&ED.C-!,CDX0S(R,48T,C$Q149!1#5"0C%%,3$R0C(Y038P(B!X;7!-33I)
M;G-T86YC94E$/2)X;7 N:6ED.C-!,CDX0S(Q,48T,C$Q149!1#5"0C%%,3$R
M0C(Y038P(B!X;7 Z0W)E871O<E1O;VP](D%D;V)E(%!H;W1O<VAO<" R,RXU
M("A-86-I;G1O<V@I(CX@/'AM<$U-.D1E<FEV961&<F]M('-T4F5F.FEN<W1A
M;F-E240](GAM<"YI:60Z,F1F-S T968M-C@W-RTT93,Q+3AF-SDM.&%F8S,U
M9&1A,V9D(B!S=%)E9CID;V-U;65N=$E$/2)A9&]B93ID;V-I9#IP:&]T;W-H
M;W Z-39E83<P-6,M,34X,"TS8S0U+3EA9C@M-3$T-C$W,#$Y9F5B(B\^(#PO
M<F1F.D1E<V-R:7!T:6]N/B \+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP
M86-K970@96YD/2)R(C\^_^X #D%D;V)E &3      ?_; (0 ! ,# P,#! ,#
M! 8$ P0&!P4$! 4'" 8&!P8&" H("0D)"0@*"@P,# P,"@P,#0T,#!$1$1$1
M%!04%!04%!04% $$!04(!P@/"@H/% X.#A04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04_\  $0@!O0.V P$1  (1
M 0,1 ?_$ -D  0 #  ,! 0$            ! @,$!08'" D! 0$!  ,! 0
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M):V#P86C-)8 */?$G&9GCP@J<T S $YH5*)S0J4+ "P@4L(038
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M!0 [8  6 !X@ !-@" #"0"2Q B#(% %%?&H[1@+@%@  >^ @!(  6;P
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MOHNA]I<^24.+.^B78Z;]6U_1)9=VKMF/*?0JV68P4MR ) 0 =L    O= ,8
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MQ/5LK"4^UU&W+@S/.#/,#RUR>K96$I]KJ/\ @&9YP9Y@>6N/5LK"4EZW+'X
MF><&>8'EKCU;*PD]KAC\ 3/.#/S8>6N/5LK"3VMV/P!,\X,_-AY:X]6RL)0?
MK:,FM*_0&9@(R_\ 4&=W_(%\M<>K96$K>ULR>'T F><&>8'EKCU?*PE)>MJU
M^ )GG!GYL/+7)ZODX2>UHU^ )?G!GYL/+7'J^3A*?:T;/[@2_.#/,#RUQZOD
MX2>UFW^ )?G!GF!Y:Y/6,G"3VLD?@"7YQ9^;#RMQZQDX2GVL4'_^/Y?G%GYL
M/*W'K&3A*2];!/\ ^OY?G%GF!Y6X]8R<)/:P3;^[^7YQ9^;#RMQZQDX2GVK[
M?_Q_+\XL_-AY6X]8R<)/:N+_ /7\OSBS\V'E;CUG)PD]JVW_ /'\OSBS\V'E
M;CUG)PE/M6?_ .?R_.+/S8>5NQ/6<G"4^U6=G[OY?G%GYL7RMR>LY.$JM^M2
MI""3_P!/Y>#>J+/S8GE;CUG)PE?VJE8_^G\OSBS\V'E;CUG)PD]JE7_Z^E^<
M6?FQ?*WGK.3A*?:H7_\ K^7YQ9^;#RMYZSD82A7K5&VA3J[@2DM((UN+.HLV
M$E)6F9]P)Y6X]9R=5)?,+[;=+^;0T9].D2+GW4>06@I<%PDSWR.VU<B2DK2)
M6XA%F#&.;+Z>(BMVETNJ^YYEUV[E_+'M?-XEX;UW9F%4KN7EJM.G(.TG2ENO
MH4>\XTZ:D+(]TC(<EV7;/8ZV7U>=;-8NE^N-@>VP]J=.ET>OMMQ;]T9"5STL
MEFL38RCS4R64_HX<#B-Q6+ >#S\S+W9[GTO2]3&=;WQK?9-P<;N@   %H!@
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M^/X4K?FY_FB\RW$\MG<,I*[5\"^ZE;\W/\T.9;BSY7.X97*[=[R^ZM;\W/\
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M LL[8 "OI'J_?OHNA]I<^24.+.^B7/TWZUK^B*L*U=LQY3Z)!&5F( L /^Q
M%@   ':   \/:  %24I#B<U1IM([;#LM :Z5WCJRF C2N\=64P$Z5WCGE, T
MKO'5E -*YQU6]LP#2N\<\I@&E=XZLI@(TKO'5E,!).NG^FK*8"3><M[Y64Q!
M&E=XZLIBAI7</=GE, TSO'5E 0;KMG?JRF((:>=-M)FXHSW[3 6TKO'5E,4-
M*[QSR@&E=XYY0#2N<=640-*[QU910TKO'/* C2N\=64P$Z9WCJR@!.N<=64P
M#2.\=64P#3.\=64!.E<XZLIB%5=*[QU93%%5.NZ1'PBK+#P6F N;KO'5E,!&
ME=XZLI@)TCO'5E, TKO'5E -*[QU=C" :5WCGE, TKO'5E, TSO'5E -*[QS
MR@&E=XYY3 "==XZLI@!NN\=5G;, TKO'5E,!&E=XZLI@*LO/&VFUQ1]DS,!;
M2N\=64P#2N\=64P$Z5WCJR@!NNV]^K*8#J+Q79N[>^"5-O32HU8@D><AJ6V3
MAH,\9H5WR3[*3")IJ9NMBZ*3I>4I&P[9!0YJ:C3KH0M;;5G-+DY\E*#+%FI>
M4I)6=H:F^Z=<N*W(R[9K%L0^@*/..T\(RYT &( L,!)8P$8 "T!4S[LNT?OD
M _F#ZP_<[;[^+QV5%1Y&TCT\OZ(>#G_JW>/N<A.Q&JFWL]EHJ;:Z7?U3;"Y2
M$9QTV2[::&G4ECSDE:D]W",\R-/<U&3,[NGZO8\C$N+>^HP*A5Z51Y$VBTQV
M0T_/;)))7JAGI3:0HR4YF%W2]&1YI8QR;T1VN+<OFLQ&B'%1=N\*U,H13'U*
MDP55>.1$7=TYLC-4@L/>%FGD%K#-)P_]';'LUVA)12'%7:F9M?L\BE8G/E)4
MG2$M"<ZTF\WNM(?<D6Z)OVXKR[]&C6S=V?7Z:O W=-5 D^DCS.M,02S%)<C$
M1GITO$K1FT5F%S.S1=ZVE:Z$W+Z[M-+O[R;)+RT>O4N[%*@R9]>E4B/5ZI$<
MT;6IK?,R4A;AJ)M*"L*Q1JPVC,9D3%9U-795T3%L16:5=/2MG-_ZW4Y]&I-W
M)<BJTMQ+%1BJ)+*F7G+<QLS<4DC6NPS2E)F:BQ#4W6QIF6(R[[IF(C3"L?9_
M?B5'J,J-0)+L>D.NL5%:<RUMZ.6<ZA*<ZUPVRPKT9'F[HN];BFY?KIJ63L_O
MRJ[OI>F[\L[L:'6RJ>:G1G&)6:;J4VYQH2>!2B+N=T-ZVM*Z4W+]W>IHQ8NW
M-O9&N^W>N11I#=W'20M$]6:1:-U6:ATV[<]+:U8$N&G-,]T7>BM*Z4W;MW>I
MHQ=LO91M+:DQX;UV9+$J4T<AAI];+)FS@[M1K61(2=N U66[@G,MQ:Y.9P_T
M61LNOPJ[-X+T+IIQXUV9:8%6AR5(:DMN&DU+5F*46!%F'?MP!OVUB,3E7[LW
M4^EPZ[<VK4FH(C0XDR7!D/L0H,EY@F7'ILAE#Q,:,C.Q5BRS>,6$6+HF&;[)
MMFE$E<&_!P)U4*@2CI],6XU.>+,,VU,&1.V(SLY9-F?=J01DG=#?MU53EWTK
MNS2')N==6D7AIMXZY7*RY1J-=MB*^^]'C:X\ZJ:_H$)2@U)*PCPF=H773%(B
M-:V6Q=$S,TBVGM<RL;.W*0F5+:J)U:B*I::U0ZK 84IJ7'4\3!I>2NQ3*D+[
MA18>Z$B^I.5,1,ZXI6.]ULJX=]H,VF4R709+=3K)6TN&68MYZPLXR-*5&:#(
MNZ42[+"PC47VZZZDFR^)B)B:SJ:%L_ON=;.[94-[RV3!3-7SVB;.*K$\3QKT
M1MGBSB5C#?MI6N@Y=]=VFE$:X-]Y<BJ1&*#*UFB'F59MS,:U=>::\PS<4DE*
M-)9Q)3:9D&_;CK2++YK2-6MBW<^];EWE7M;HTE5VD(-U50L39H27HS=)NW2&
MT2NY-PDYMN"T7>BM*Z4W;MW>I.[BBK74O-=^%"J-<I;U/A5(B5"=>-%KA*22
MRM01FI-J3)2<XBM+"$71.J2ZVZV*S%*M;FD?I;1?M'\Q07_3*Y?UPXA,OG;\
M ]WROZ)?&/\ @@E)PE.B?Z!WP2^ %I.!HG^@=\$O@ I.$HT,CH'?!+X J4G"
M30R.@=\$O@"L%)PE.B?Z!WP2^ "DX2:&1T#O@E\T"DX)T3_0.^"7S1"DX(T3
M_0.^"7P"E)P-"_T#O@E\ 5*3@:%_H'?!+X JE)P-$_T#O@E\ +2<)-"_T#O@
ME\ %)P-$_P! [X)? (4G T3_ $#O@E\ %)PE)M/] [X)? !2<)1HG[/B'?!+
MYHI2<#0O] [X)? !2<)3HG^@=\$O@$*3A*-"_P! [X)? *4G"0VGS_H'?!+X
M *3A)H9'0.^"7P 4G"4Z)_=8=\$OFB%)PDT+_0.^"7S0*3@C0O\ 0.^"7P"U
M*3A+Z1ZOS;R=M%T34RXE)2'#-2FUDDO@E8S,K!PYWT2['31/-M?T.4HC4K"6
M/?(>6^@1:6^64@5.<6^5G;(!%I;Y=C"0!G%OEE(!)F6^6401:6^64A0M+C%E
M( M+C%E(!-I;Y92!#.3;C+*0*R49:5&$L1[I C0U)WRRD"EI;Y92 +4[Y92
M+2WRRD 6EOEE($+2WRRD 6EOEE(!-I;Y92!0C*S&64$1G)+$992!4FI-F,LI
M AG)WRRD"AJ+?+*0"IJ38?=%N[I *LF6B3A+%OD"+YR=\LI IG)WRRD 9R=\
MLI !&G?+*0!G)WRRD FU.^64@$6EOEE( M3QBR@A:1[I92!0U%;WQ92 +2WR
MRD 6EOEE(!)FG?+*0(S49:5!6EB/=(%7SBWRRD 6IWRRD 6EOEE( ,RWRRD
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M32M-#BBB+ 1.,@4L ?2?5]_?3=#[2Y\DH<.=]$NQTWZUK^D@\E](
M     ,58)#?ZI@C:T%                0>+\@#*)]';[7YP2&P*     *F
MXE-MIV9N$[<& !T[=\+INRM1:KM.7-MS=63+8-S.WLTEVV@E8=QGX;+,(*L
M     ,5_2&NTH$[6P*                @\1@,XWQ".T"0U!0
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M%*3$VZ?%:?=2X$&_UW[OTF&_%K$*]3-,0N)$F0TNP+%$K3R'C-*WS,B4E;6
MR$BZZ;9F<%FRR+XB->]A,=F/:ZFZ%W+ERF[F4>L78149%Z(]X9U2JIO.MRK*
M7(D$REDR/-39HK%JL.TAJZZ[3,3JHQEY=D[L3;7>WM/A*UWKG7-O,Y1;SOTI
MJEQY=VY]870V$OR(CLN"^IE*R:09NK222SG$)5OF%U]T5CO+,NR^EU*5MF:?
M]'!>@;/8CE[KQTV[Y5:'2J+3935-FLR8,-JI3'R:=<:;<43FA,CM22C%K=HB
MO:S2R-Z8BM(C1,4TZ737#GP[RSV*)>>"4VFTJ$N)=:-JS[]*A3)D@E9\UN-\
M(:7,XT:3<.RW$-7Q2*Q^+&72Z:71HC5HT1XN3LZIM3H>V&=23CE%K%/BUIHH
ML%1O$T\W$<L)A16F=GZ.Z)F3$V5\&LF)C-IVTEZ.YC-;KE$N,U?W7%5UZ\[S
M-VGYQK:J:Z3J;AR^[58X;*7B1FF>#.MLW1F^D3.[JII;R8F;;=_7O32NNE-+
MI*9<^@7@NE0S@4U,!;4N,S>ZI3FWV)Z=;F+;2_%>5\"XPM-B<TNZ(\(U-TQ,
M^QFW+BZV*133IF=>OLG!WM?N1<Z=>*G77NQ1T>DS%;?A:H[$FP*>_3H[2EJ*
M6\\9FX\G-SO@>_+$,1?=2LSHHW=E63=%ML::X3$4[\43KJW"AUJZM4DTA+D*
MO428\I$6#.\E-U)F6<=B0_$.V0F.9%8O#A/NNP+%UU)TZI_$G+LBZW1HNB>R
M:5\&U(V?70H$*5,OS3&5SG*\_2:E"A1I=2;B1VVDK2B&<<[6W%9V<E3O:$F^
MZ?IP6W*MMBM\=M-4S3PP?#)C<=J;*:B&LX;;SB(QNEFNZ)*K$YY;BK,8[+I=
MK([ 5 (GWP4L!#W@4,@ !!@B0'TCU?/WT70^TN?)*'%G?1+L]+^K:_I*/(?2
M   @R(\>X 9I'O@&;V3 + "P!(   /SYZS.R"^.U=F[2+HKAD[279#DI,UQ3
M5J7DI26;81VX2'-EWQ;.ET>KR)S8B(['P(O5$VU%N4<_]95S1S\^UYWIV9C"
MY>J1MI+]&D'_ *TKFAS[4].S,87+U3-M1?H4CQI7-#GVX'IN9C"Z?5/VU%_1
MTCQI7-%\Q;@GIN9C"Y>JGMI+^BI!G]J5S0\Q;@GIF9Q0N7JK;:2_H:1XTKFA
MYBW!/2\SBA=/JM;:2_H*1XVKFB^8MP3TK,XH7+U7MM1?Z/2/&U< >9MP3TK,
MXH:%ZL.VDOZ"C^-KYH>9MP3TG,XH7+U9=M1?Z-1_&U\T7S-N">DYG%&Q8O5H
MVTE_HU'L^UKYH>9MP/2,SBA<O5LVTE_HM'\;5S0\S;@GI&9Q0L7JW;:"_P!$
MH_C:N:+YJW!/1\SBA;V<-M.Y$H_CBN:'FHP/1\SBA*?5TVT&1&4.CV?;%'_-
M#S48)Z-?Q0L7JZ[:/J='\<5S0\U&!Z-F<4+%ZN^V@O\ 0J/XXKFAYJ,$]%OX
MH6+U>=M./4:1XXKFB^:MP/1;^*%B]7O;27^@4?QQ?-#S5N">B9G%&Q8O5^VT
MI/.*GT>TO_.+X \W;@GH>9Q1L>1O#L<VH[.Z<_4:[2$3;NK<4[I*,I4M<'/P
MJTK=F<;9G^DDCL%R\^V9IJ9ZG[;FV1%T?-/;1\VFUNCN)S6IK;CAX":1G*=,
M][,(LZWL6#GF8>?;;=6E)J^]^KEL)K<^\D':3?6 Y3*-3OAJ!3):<R3)D*+N
M9#C9X4(26%!*PF>'$.AG9L3HA]'T/1W6SOW_ (0_9@ZCW     !BOZ2WVE C
M8%                0KO3[0#.-\0CM D-04               !@Y])9[2_
MS"#^8.W\O\;;[_WB?R:![&5]$/F>H_6N\?<^=D0Y7"DB!%K $D0"2(438")L
M 38 L1$ M8 6"HM8 FP!)$"+$0*DB!$D0";!1-@"2($6(B =U='_ )II'^?_
M )BAF_Z9;R_KAU<63)AO)E0WG(\II2C:?94:'$&9F1YJBPD(U&B="\69-@J<
M5 E/15.V:53#BFS7FJSBSLT\-AX2[($3,:G,1>.\;<%ZEMUF<FER,XI$$I#F
MKN:0\Y><BVP\X\)[YB;L:Z+O74I6:.([.J#^L:>8^[KA(*9GN*5IB:[S26GW
M6;9W-N(6B3-7,DWEO--3#;F5N?(13C)5/2[)<64=22L(VK5=R9%B,A-V,&M^
MZ:5F=#B(J%1:4PMJ8^A<5+B(RDN*(VDO&9N$BP^Y)9F>=9C%I#-9Q3'J=4AN
MQ'X<Z3'>I]I0'&75H5')1VF31D?<D9XR(2D$3,4I.I>;6*S4GI,FI5&5,D3"
M2F8[(>6XIY+9VI2X9GW1)/"1'B"(B%FZ9UR4VL5BBO+DT6HR:;)<0;;CT-U3
M"EMGC2HTF5I=@)B)UD73&J:,HLZ?"F)J,*6_&J2%&M$UEQ2'R6K&>>1YUI[N
M$5(F8FL:VTFLUJ=/15IM3ERJLV5C<]Y]QR0@K++$K49F16;PE(B*$S,S69TC
M]9K<JFL4:54Y;]'C'GQJ>X^M4=M5MMJ$&=A8<(4BM29F8I,Z&\J\MYYVIZ]7
M*A).G&2J>;LEU1QU)Q*:,S[DRWR"+8CL6;KIUS.A<KVWM*H%5BO!42JI)4VF
M;K3NG)M>%2"5G6YI[I";L4I1=^ZM=Z:L8%X;Q4ER4[2JQ.@NSK==<CR7&U/F
M>,W#(^Z/LF+,1.N$BZZ-4S%77&9F9F9F:C.U2CPF9GC,S,5#=!$ )P J 1)X
M04,@#"8(@!(*^D^K]^^FZ'VESY)0X<[Z)=CIOUK7])!Y+Z0
M8J^D-_JJ!&P*                A6(^T RB_1V^U^<$AL"@     >(!U:+N
MT%N9K[=)A)FVYVM)CM$]G;^>2;;?R@.S+$ D      8K^D-]I0J-A%
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M<H4*LU2G5.H4:$D:2585N [3(@H5?AW:^7^*5ZK/KI_R$CV,GZ(?$];^XO\
M'W/'$0YG47)(@T(A472D$:$0"Y)!%R(!H1 BY) :$0(N1 BY)R@-"2"+D6\
MN201J201<B :)2 T)((NE((T(@'-I:?]X,'^O\FH9O\ IES9'ZEOB^2I[W\I
M^^,NTL" *@!(( H" *6  (     !@H"%@!@!0 !       >ZV+?O5NQ]H7\F
M8X<[Z)=WHOU[7[;5WQ]L>8^O+=T    ! ";3 +2 0 D! "A_&H[1@+@)Q@
M  %H" $@&YV0$EV0$ ( 2 C< 5:^+1V@1<_=!3& @!)  !8 6@ !N !XL
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M.P[;#%MNB=3.9E7V4WHI5%,+^OL_Y?R:A+_IEKI_U+?%\A1WOY3]\1V%K0
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M(C_T%_=_('*NP/.Y''"_M%[*.L)GB+_ '+NP/.Y''![16RCK"9XB_P  <J_
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M(JHZVVFT3.\T+ZCS733;8LB+ ,VYL3-')F=)=99-TSJU_CA/:\(.9TP$
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M<^34,7_3+GR/U+?%\21WOY3]\5RPN0* @ @%2" * @    "@(
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M3^H[\FH8NU.?(_4A\$;[W\I^^-BP" 4 .R D$       M!0$+ 4!$ J00
M   4!   >[V+_O6NQ]H7\FH<.=]$NYT/Z]K]WCRGV8             P,S5(
M09$=A$9&>\ W  $&=FX8!: &=@!;V# 2 BWL& 9W8, M[ !;V# ,[L& 9W8,
M /"64!E&(TLH)1&1D6$CQXP2&P*BT!(  J:K-PP'SB\FWC9?=>:Y39M:*546
M3S9$:G-.35-J+&2U,I4DC+=+.M(;BRZ=4.MF]3E9>BZZ(=E<[:[L^OX^<*[5
M9:D50DFM5->)4:7FEA,R:=)*E$18\VVP2;9C7#>7G69GTS$O;$=I$>^,N9(
M     Q<^D-=I0)VM@4               !!XC[0#*+]'1VOS@D-@4
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MKP>/KX!V.7;@\3SN?Q-DWWVB'COS>#S@O@%Y=N">=S^)J5\]H1X[\WA\X.<
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MP[(     Q<^D-=I0)VM@4               !!XC[0#*+]'1VOS@D-@4
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MU0(4ANZEY*LHC*%4*L:(I[BM7;)"U%V+3L_(.AG3\S['[9;,9-<9?H\<#U
M   !BY](:[2@3M; H               "#Q'V@&47Z.CM?G!(; H
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MJ4HS4H]\QT)FLU?666Q;$1&J'="-     #%SZ0UVE G:V!0
M  $*Q'V@&47Z.CM?G AL                 P<^DL]I?YA!^-MJ!?XC7D^U
MG_(2/:R?HA\%U_[B_P ?<\J16CF=)H2<H(T2D!H1 C1*;0&A)!%TD"+D0"Y$
M T20#1*05JE(BM4I$5H205JE(BMDI$::I2(TU2D1IJE(BPT2D16J4@K=A/=J
M_P V]\DH9NU.?)^N'YO;[POR^^.9PPO:  %H    * B 5((6@ " 5( " !:"
M@(@!.  !0$    >ZV+?O5NQ]H7\FH<.=]$NYT7Z]K]X#RGV8
M Q5]);_5,!L                 A6(^T8#*)]';[7YP2&P*
M    Q<^D-=I0)VM@4               !"L1]H!E%^CH[7YP2&P*
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MHE(+1JE(C35*1&J-FDV&O_-/?)*&;M3FROKA^96N\+\OOCL.K"X* @
M%H   '9!0P $        +0 %  ! #W>Q?]ZMV/M"_DS'#G?1+M]%^O:_;AXS
M'F/L$8     #   ( 3N )P6 ( 9G\:CM& T( /"8  %@! %    "*T!-@" #
M&  (/%E!%6OBT]H!<%  NV =H  +,@  6V8   LL,  , " %%?&H_* N  )]
MP , L  $ ) ,  0 0!N@   HS\6D$7,%       L   L8  D\!X $8P$ !V9
MZ?U3]\A!^4-I9?XA7C^UG_(2/8R?HA\'U_[B_P ?=#S!$.9TFB4@BY)!&A$
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M26QT\5;>\3?YH<N[ \WD\4)+UD-C_73_ (F_S0Y=V!YO)XH3[1^Q\_[9?/\
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ME8!1[6Z5UE74@/17JW4KP3)3NGDU&L/$\\:B+-)*"224H01%WI"J]!: $>$
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M8O\ O5NQ]H7\FH<.=]$NYT/Z]K]MGC,>8^P+-\ L/&  %A_D  $E[P(C=!0
M -X!UU4HM%K2F&ZU38M20SG&TF8RA\D&>,TYY'9:"3%=;A>@EQ+/^5Z3XDSS
M0K*;L8(]!;B_A:D^),\T*RN[&!Z"W$/[KTGQ)GFAI-V,$G<2XA?=>D^),\T*
MRE(P1Z"W%_"U)\39YH:5I&!Z"W$Q>BU*\39YH:4I&!Z"W%_"U)\39YH5E:1@
M>@EQ3^ZU)\29YH5DI&"/02XGX6I/B;/-"LE(P/06XOX6I/B;/-#24C ]!+B?
MA:D^)L\T-*4C ]!+B;EUJ5XFSS0TE(P/0.XOX6I/B;/-"LE(P#N)<4B.VZM)
MQ?4V>:%96D8*M7$N+HTVW7I.+ZDUP!64I&"WH'<7<NM2?$V>:%96D8)] [B6
M_P#*U)\29X JE(P/0*XA?=:D^),\ 5DI&"/0.XEO_*])\2:X K*TC 5<.XBD
M+;.ZU)-MQ)H<3J;-AI45AEWH5E*1@^75?U:Z>MY:[H7GET&$LS,J9):34&&[
M=QI2S)24EN%A'/;GW1#R<W[3D7W5BMO@Y=U/5PNK1:DQ6[TU!^]M2B+)V(Q*
M;2Q3VW$X27JZ+26I)XL_!V!+LVZYS]/]ORLF:QIGO?9SM4><K"H\9CA>B@\0
M!A    M 9J^,1^4!IN  !;@ ,(  8;.P 8K0  Q@ "< " #$  ,V?BT@C0%,
M%@@'AM%#<    P@%@  &0    "I]\GM*]\A!^8]HD.6Y?NON(C.J0J49I4E"
MC(^Y3B.P>QDS&Y#X/K[9\S?HG7[GG2@3OJKW(5P#EWH='=G"5TP9OU5[D*X!
M-Z,5W9PEJ4";]5=Y"N -Z,5W9PEHF!-^JN\A7 )O1BN[=A+5,";]6=Y"N -Z
M,5W;L):)@S?JSO(5P";T8KNW82U3 F;L9WD'P";T8KNW82V3!E_5W>0K@#>C
M%K=G"6B84OZNYR#&=Z,5W9PEJF%+^KN<@^ 3>C%J+9PEJF%+^KN<@^ -Z&MV
M<):)ARN@<Y!B;T+NSA+5,.5T#G),3>A=V<&B8<KH'.28F]#6[.#5,.3T+G),
M-Z%W9P:IAR>A7R3$WH:W9P:%$D]"ODF)6%W9P:IB2.A7R3$K#5)P:IBR.A7R
M3#>A=V<&A1)'0KY)AO04G!HF)(Z)>03>AJDX--4D$S(,VE_$/XB,S^*4)-T.
M3+B=Z'Y0:I]2T96P9!8\;2]_M#M[T8NA$3A*_D^H_4I'@E\ F]&*[LX2>3ZC
M]2D>"7P!O1B;LX2>3ZC]2D>"7P!O1B;LX3L/)]2^I2/!+X WHQ-V<)V'D^I?
M4I'@E\ ;T8F[.$[#R=4?J4CP2^ -Z,2DX2>3JE]2?\$O@#>C$W9PD\G5'ZE(
M\$O@#>C$W9PD\G5+ZE(\$O@#>C$W9PG8>3ZC]2D>"7P!O1B;LX3L/)]1^I2/
M!+X WHQ-V<)V)\GU+ZE(\$O@#>C$W9PG8CR=4?J4CP2^ -Z,3=G"=AY/J/U*
M1X)? &]&)NSA.P\G5'ZE(\$O@#>C$W9PG8GR?4OJ4CP2^ -Z,3=G"=B/)]2^
MI2/!+X WHQ-V<)V'D^H_4I'@E\ ;T8F[.$[#R?4?J4CP2^ -Z,4W9PG8>3JC
M]2D>"7P!O1BN[.$I\G5'ZE(\$O@#>C$W;L)1Y.J/U*1X)? &]&)NSA)Y.J7U
M*1X)? &]&)NSA.P\G5+ZE(\$O@#>C$I.$['N-C4*<UM3NTX[$>;:2^LUN+;4
ME)%HSQF96#BS9C<EV^BB>?;HE^U#6FT^Z+*/-?7F>C=464!&>CC$ DEH+=+*
M C/3QBR@))2>,64 ST[JBR@&>DMTLH!GHXQ &<CC%E ,Y/&(!FI:-*CNBQ&"
M+YR.,0*G.1QB!#.1QBR@&>CC$"F>CC$ $M!?I%E 1GIXQ90$YZ.,64 )2.,0
M :T<8@$9R.,0"<Y'&( SD\8LH"#4@BPJ+* HTI.B2><64$7SD<8@5)*3;WQ9
M0 UIXQ90$9R>,64 SD[Y90#/1QB 2:T<8@$9R>,0"<]&^64$"4CC%E #6D]T
M@5&>GC%E 3GHWRR@,U+1I4=T6(]T$7ST\8LH*9Z>,64!.>CC%E ,].ZH@$9Z
M.,64!.>CC%E ,]'&(!&<CC$ 9Z>,64!.>C?+* $M.^64 ST;Y90$9R.,64 S
MD\8@11E2-&GNB :$I&^64%,]&^640,Y.^645 E(W5$ 9R,5I904SD<8LH!GI
MWRR@(ST\8LH!GIXQ90$YZ.,5O; ,]./.(!&>GC%E ,Y/&+* C/3GEA*PB,\?
M9(1'\X-O=XKQ1-L]\X\.L38\=NH*)MEJ0ZA"2S$X"2E1$0^MZ/+MG)MF8C4Y
M8BLOGA7JO7U]4?&WN<.[RK,(:W5RO5>KKVH^-O<X:C*LPC8NZT*]5ZNO:AXT
M]SAJ,FSAC847*]5ZNO:AXT]SAKDV<,;"C0KTWJZ]J'C3W.&^39PQL*+E>B]7
M7M1\;>YPO)LX8V+1HF\]ZNO:AXT]SAN,G+X8V%%RO/>GKVH>-/<X:C)R^&-A
M1<KS7H/^W:AXT[SAKDY?#&Q6A7EO1UY4/&G><-<G+X8V%&B;R7H/^W*AXT[S
MA>3E\,;!HF\=YNO*AXT[S@Y.7PQL&J;Q7FZ[J'C3O.$Y.7PQL&B;Q7FZ[J'C
M3O.$Y67PQL&J;PWDZZG^,N\X3E9?#&P:)O#>3KJ?XR[SA.59PQL%RO#>/KJ?
MXR[SA.59PQL%_2"\77,_QEWG!RK.&-@L5X+Q=<SO&7><)RK.&-@L5X+Q=<SO
M&7><)RK.&-@N5?O%UQ.\9=YP<JSAC8KM;N5ROKKU/2NKS5)-:[4JD.&1_!JW
M+1PYV79N3HC8DZGS9-Z[U$5A5VH6$9E]*=W_ -8<G)R^&-C,1H3Z67KZ]J'C
M3O.$Y.7PQL6AZ67JZ]J'C3O.#DY?#&PH>E=Z^OJAXT[S@Y.7PQL*'I9>KKVH
M>-.\X.3E\,;"AZ5WKZ]J'C3O.#DY?#&PH>EEZ^O:AXT[S@Y.7PQL*'I7>KKV
MH>-.\X.3E\,;"AZ67JZ]J'C3O.#DY?#&PHGTLO5U[4/&G><')R^&-A1'I9>O
MKVH>-.\X.3E\,;"B?2R]?7M0\:=YP<G+X8V%#TLO5U[4/&G><')R^&-A1'I7
M>KKVH>-.\X7DY?#&PH>EEZNO:AXT[SA.3E\,;"AZ67KZ]J'C3O.#DY?#&PH>
MEEZ^O:AXT[S@Y.7PQL*'I7>KKVH>-.\X.3E\,;"AZ67KZ]J'C3O.#DY?#&PH
M>EEZ^O:AXT[S@Y-G#&PH>EEZNO:AXT[SA>3E\,;"AZ5WJZ]J'C3O.#DY?#&P
MH>EEZNO:AXT[SA.3E\,;"AZ67KZ]J'C3O.#DY?#&PH>E=Z^O:AXT[S@Y.7PQ
ML*/I7J_7@O!.VR74C3JM,DQER'"6R\^XXA1:)6-*C,C'0^X9=D=/=2(<=^N'
M]&=78Z)')(?$I0U=CHD<D@*&KQ^B1R2!*&KL=$CDD"T-78Z)')( U=CHD<D@
M#5V.B1R2!*&KL=$CDD!0U=CHD<D@*&KL=$CDD"FKL=$GDD"48*CLZPV6C39F
MG@L(!OJ['1(Y) 4-78Z)')("AJ['1)Y) 4-78Z)')("B-7C]$CDD!1.KL=$C
MDD!0U=CHD<D@4U=CHD<D@*&KL=$CDD"4-7C]$CDD!0U=CHD<D@*&KL=$CDD!
M0U=CHD<D@6B%1V+#^"3BWB!*,HL=@V&S-M)G9O%OBD0VU=CHD<DA%-78Z)')
M("AJ['1(Y) &KL=$CDD :NQT2>20"-78Z)')($HG5V.B1R2!35V.B3R2 H:N
MQT2.20!J['1(Y) E#5V.B1R2!35V.B1R2 -78Z)')($HQ6PQK#9:--EBMPA1
MMJ['1(Y)"*:NQT2.20!J\?HD<D@*&KL=$CDD!0U=CHD<D@*&KQ^B1R2!*&KQ
M^B1R2 H:NQT2.20%#5V.B1R2!35V.B1R2!*&KL=$GDD"FKL=$CDD :NQT2.2
M0)1!QV+#^"3R2!649A@V$6MI/!O%O@D0VU=CHD<D@6AJ['1(Y) 4-78Z)')(
M U=CHD\D@2AJ['1(Y) IJ['1)R$ :NQT2.20!J['1(Y) &KL=$CDD :O'Z)'
M)($H:NQT2.20%#5V.B1R2!4:O'Z)')($HR6PR3[22;225$JTK"PV6"%'\P_6
M"3;MKOK_ 'BK^0D?:]#'^"WP;MUR^<DD=Z(<BY)&X@:$@:H-"0-4&B4#40-"
M0-1 T2D;B!HE U0:)0-45JE (U2CL!4:)0(-4H&1H2!!JE(@N21!<B 6)(@N
M21!8D@+DD0=M=HK+P4_]=?R:APY_Z<I.I\K+%^4_?'*6ZD@T   " * @
M    "@ "    H       #Z?ZNO[Z[H_:7/DE#S_N/[>YPYFN']+Q\*@
M        Q5;K"/U3 ;                 (/$?:,!E%P1V^U^<$AL"@   (
M,S+< >0O/M4V=W,D%#O1>6!39N[$=>(WR(\)&IM&<HL>Z0MMLW:HJQ=?;&N7
M.NO?NY]]6%R+IUN%6$-87DQ'DN+1^NCOD_Y1!,4T2MMT7:I>A2><1'OB-)
M    &+GTAKM*!.UL"@               (/$?: 91?HZ.U^<$AL"@
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M\%5I+3V#'P&;ESEWS;.N''9=6-.M]#'&V     ,7/I#7:4"=K8%
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MH<^24//^X_M[G%?KA_2X?"H             ,5?26_U3 ;
M   (5WI]HP&43Z.WVOS@D-@4     44C.(TG89'N&5I +)(RP;FYN )
M  !BY](;[2@3M; H               "#Q'V@&47Z.CM?G ;
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ML=?J/TKO!V>FC_-9X^Z7S?=/MG[XYX=6_6"L     HBT0"  $@     " $@
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M\20>)*C+&E5EJ%;I=D?*9N5=E73;=%)A]KT_469]D7V:GMB'$[*;,-@"+ $
MBK6%M/: A>S_ .0*%C!#&"IL+': C"  !F"(!4X-P P '9W "PP"PR 9J^,1
M^4!H   !@W,(![X 8      ;A (  $@*,_%I!%[04 2=G:,!   %A +=P P@
M   6;P!: =D!7],OU3]\A!_/O;FC.VNWP(]V;9_W:1^B?;/VUG@_+?N\_P#Z
M\SQ]T.SCWPN!4I=!O9>9BIG>J[K$9A5,AI:.#4'*?]'<4\I1*:+ G2D256V8
M!QST^?;%UEE-V^NF=<5UZ.WN<]O5]-=NYF9O;]D1HC5--4_'V%/VEP2F7-J5
M4C/KFT.NU&N5?0D1(<*H.I<)+)&>,K-T+^ANF+XMF*76Q;'X-9?W.V(LFZ)K
M;====3\TU<-^\ESJE1Z+-J!5%N]EW$+8IT1A+1P)*2E*DM+<6I6<BPEYKB4I
M.WL#FC(S;;[HBFY=KQC13_T<%W4Y%]D73O;]OTQV3IK'_5W,^_MS&G:M4Z&U
M4G:G>JHP*A7&):6TLPFH4@I+C;"DJ,W5+67<*42<U. <-G29TTBZE+(F+:=M
M8IIP<MW7=/'S6;TS?=;-U?[=V[>_'X-57]N-6929=?:JD<Z->"?>"AMP2;5K
M34UU+Q1W\Y1:-:5(+X0K>YW!/*9UD4LW9WK8MNKV4BE8^!Y[ILS]3>C=ONNM
MIVUNK3Q>TIDVF7BN$U(DN,T^5/:J[L^\C"XKA4Q,M:EG$6AY1/%I"(D'HD_I
M8-T=.^V[+SZ1IINTMT_-3MT:-'>[^7=;F]-69I7?K=%/EK-:373W:'@KQU]I
M>RNZU+-+?I!52S*H\A1*<53:0M3<%+A6]SWZCL/&22/>'HY&3/F;[O[;=7_N
MN^IY/4]1_P#DR[?[K]?_ +;?I?.TE;A'K/"B:KD@5:-"0"T7))$ N20%R2 N
M214E<D +DG!A!*KDDQ4:I;Q"56(:I;RC-6J-DM[HE6J-4MB#M*$W_OB&>\I?
MR:AU^H_2N\'9Z:/\UGC[GS2B'2/+-..OZ3R'K+?E+0_&:MI"TF;9AQ;PY\S>
MW)W/JIH=?*W.;&_]-=+Z7>6Y:JW7(YLQJ/1;H(C2Y[-YJ)I)$1^FQ>Z[IO.-
M1R$$9)-"LU6<>$>3D=3N63INNOK$;MVN)GW/=ZKI(S+X^FVR(NG>MU3$>^,-
M"E(N;1Z=%K=7ARD5V[U4NG5)U&F2&- ^U)BOMLK);1FK,<;5B4D\1X!<SJ;[
MIMMF-VZV^V)T]DQ5K)Z++LWKHG?MNR[YC1VQ2/8I5=GM-9J4VIWBJL>AW?IY
M4B-I*?#6\3LJH1D/$DFC65A$FU3JS/M$8MG5W;L6V1-UT[VN>R)IK_HQF=!;
MOS=F71;;;NZK<8KJKV=KIKZOP;K;3J[J5+@3J?&D&TS!DM*5#-"DIL4E"5),
MM\L. =CIHNS>GMK,Q,]O:Z7576Y'574MMNCOC1J=]M,HE.>FWO;H],IU#IUS
M"@NMMQ&7"?EE4=$C-<<4M7>&O.+ .KT6;=$6;TS=.977.B*5=_[AD6W3F1;%
MML9<VZHTSO=]?<X*-EE.C2*HFM7D*'$ISU-BMNM1%OK??JS).MD2246:2+;%
MF9]H<L]==,1NV5F=Z=>K=EUK/MEN]=%]](MF(U:]Z/'L6J&R%29+--H-<:JM
M3;K3=W*HE3"X[+$MY"G$N-K49FMHD(5G'81VEB$L^X:)FZW=C=WH\/BWF?:8
MK$67;T[VY/CKKL8Q=F='K<JE%=>\Q3Z9,J?D.?,D151U1I6C4Z3J6\Y6>RM*
M%9IVDK!A(:GK;[(NW[*3$;T:=<?%B?MN7=-O+S(F)G=F:=M*U\*,CV>T%ZA5
MF\5,O!(J5,I;JHK9QJ>I3I.H3:;DEO29S+"C[E#F'LV"^<OW[;)MB)N[_P"F
M,I/V_*W+KXOK%N%LX=N$/GQ';A]X>H\*4 @8!O )   !&Z"I%0$       ?1
M=@W[X+J?:5_)+'E?=OVM_A[WM?9/WF7X^Z7[^5WQ]LQ^</UI*")2TI/$9D64
M4?*)6T6O1T9QKC6IOI)NTLC;(SU!AA;J2LM^,[DC-6\(/"T_;C?>;02A2U0H
M-\V*=K4XTL$MHRE2D(B2V4*.PVS:78:3/OR%2KN)VT7:G J$VY-,.G5Z]U/\
MHL,S6F4QTSELL-/L_!FK,0^V2U9S9*S5'80BN5=*_%\K_5:GW>NW>>,R=*IW
ME&\%3G4E#4J7*UI3#D)<4UD4?09II=6A2NZLLP& YT6_-];R4BZE.IDZ%1[P
M7IG52.JM+C)DMQX]+4H[&V%*)*W'"(B+.,!T,':M?A;] G5V7'IMV=++I,^K
MQ8294*HUF(ZMM#3JS5GQ&WB2E3:TI4G.M+M NW?3:K>2[MTW?+Z*=5KU2I']
M9G49A#3#,:,MXFV4DX>D:49$1NJL.S< ?5MGEYY-\;FTN\4YAN/.E$XW)0P9
MFPIUAPVU+:MPYBC3G)%1Z<S!7Y5]=/XFXG^?F_R4#U_M/ZT^#Y[[[^C'_N?F
M%G&1CZ^U\9>[-BVW'N#GAUZ.RCF9V81RPX9=@P9CL0ZUSFM&8W#C<MLS&W&X
M=XE+73&XA*,DS9+$9PR.SX-:RSB_*16#I=9]%.*8AWNC^NO#$RY<Q"6ST;9$
MEMLLQ"2*PB2G 16#MTB(I#IZ9FLO-U+O5#K9KN9+Z!ZK-:E4W;&FD,J/4J_3
MY#4QO<-45.E;59OE99;V1\A][LBEMW;J?9?8,R8ONL[)BK]PX+>P/F7V2,)@
MH @]WM *M?%I[0(N8*     'Y0 P   + "W!8  ( 4/XU':,!I8 8@$ ) "
M "W< +;   M 3@P (   !FU\6D$:&8*%[@!;88  8 #" G\P" #'^0  +0
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MLR,S/.61G:=H*X7_ $CV9^3TTKT=:\FMO:TU'T\C-0\9&DS0>DM21D=AI([
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MKY_Z=SL]-^K;XOB98"R^^/1>1.M(,@    !: @@4Q@B0 ! !C 2   !N  "
M$V   * @  #Z+L%_?!=3[2OY%8\K[M^UO\/>]K[)^\R_'W2_?QGW1]L?G+]:
M09@    )(@$8@#M@ !C,P"S> 4-5CJ,!'@/&1'[X@USOX*.0G@"D%49W\%'(
M3P!2 SBXJ.0G@"D!G?P$<A/ )2 SOX*.0G@%I"U,XN(CD)X W82IG?P4<A/
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M]X.J9G@'. 7G9?%&T\OF<,[)/1Z\'5,SP#G '.R^*-J^7S.&=DA7>O!U5,\
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M!E$^CM]H_?!(; H               #%SZ0W^JH$[6P*
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MDWQ-OTW>Q^C_ &;KKLZR;+]-UOMA^KQX[Z(  $'^8P&47Z.CM?G!(; H
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M=MF>ZFCQKV3#KV9G,LOFZZ(C&NFOAVQ+X4GO2MP#W'S$I   !((@% "P
M      ?2_5[_ 'T70^U.?(K'F_<OV]W_ #M>K]I_=6>/NE_2@? OTY%F&W=
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M?(K'F_<OV]W_ #M>K]I_=6>/NE_2<? OTX 186\ 9I;P!FIW@#-3O &8DMP
MS4[P!FIW@ B(L1 ) ?(=MVQ-K;(5#9<KCM%=HZWG4+;83(TA/)2DR,E*3998
M.QT_479%V];K=+J^DMZFW=NU/E2?4G)&*_<CQ!OYT>E'WC/C#8\B?L&1/;=M
M:I]2]Q/>W[?\WM_.C7K?4?EV,?QWI\;MK1/J;R4XK^/>;V_G1KUSJ?R[&9_\
M:Z:?[K]K5/J?STXK^N^;V_G1OU_J?R[''/\ XOTL_P!U_P#\FA>J+4DXK_.^
M;F_G1?Y!U7Y=B?Q;I>*__P"2Y>J95BQ7^<\VM_.A_(.J_+L/XMTO%?\ _)+O
MJG55YE<=Z_BUL.I-#B/)K5BDJ*PR/X49N^^]1=%)BVG@U'_C'31,3%U]8[W@
M;W; ]H]PFFF:4RY?2[S2"2U,B(2W4&B(N]=CYQYR2LP*09]D>AT/WVVVW<SH
M_&'E_<?_ !W,WM_(G>K_ &SH]KQ,+9IM0O5**#1+H3VW%GFJDU%&IQ6^RM;E
MF+>*TQW.H^]=-$?+6Z=CI=-]CZNZ:76Q9&-:OU]L2V-P=D="?97(*HWGJJD/
M5JII2:4*4@C)#323PI:1:=EN%6,]XOC.IZB_/OW[GZ!T71V=-E[EOX][ZF.L
M[H  (5P@,HGT=OM'[X)#8%                8N?2&NTH$[6P*
M       A6(^T RB_1T=K\X)#8%                8.?26>TO\ ,(/PAM?3
M_BK>PS^N%\FD?IOVO]IE^'O?C_W;]]G>,?T>-)(])YC5*!%:I;&:M4;);$6C
M5*!&FR4"*U2@2JT;);&:M4:I;WA*M1#9+8S5J(;);&:M-D-B5:B&J4=@16J4
M#-5HV2WV!*M4:I0(U1JE BMTMC-6J-D-C-6XALAL16Z6^P)5JCDQT6*</>8D
M'_W*QP9T_)+L9$?Y(\7XY1WI?]MT>H\>=:01(( (!0  2"(!3=     38 @
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..QHS[%9EA'9N6VX0'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>fc_product-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fc_product-4clr.jpg
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M_\0 SP !  ,  @,!              $" P0%!@<("0$! 0$  P$!
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MZ]PP"J@$T4 L"N#,-128U#,JD[6GL)!)156R>V FJM\>V FJM\>V GOM\>V
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M)-=4%6H0(G2"PG2(J0       <29\M%_#/XI@DK8>Z8J+$0"2(P58B/9!$T
M3I!4T!4T$         !Q)'ZQ'_\ V?%%9E>FR"IT%K B2(P%B3L&9>P L"FD
M!-#!4T$         !PGR_P",C?@N^XD5F6A)+5 7IW  B5[ "Q)US/2"K%4
MT@)H8BIH          .OE_\ <X/Y.1[B!69UN10@$T+6(!.$P$DG9!5J:/M
M)*NI0!-#!2@@D        !PW/^Z1OW>1\=D$Z7QZQ]=ZQ9/:1D^1DR=,?RZ1
M6=V6W,80V\N 7-U.)2I-2)1HQ$1Z1VIR9G2Z7B;;=&#4OK_Y>ULAW'IL?@B<
M"<3Q=N"2^O\ Y>]!+CTV/P1>!.)XNW!/K_9?]!+CTV/P0X$XIXNW!/K^Y?\
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M     $Z=D00*%3 21B!I%%%?*-^PK[0(M4P4 3W/;$$"@   ![   &  %3
M$Z=D! "B_EFOP5_:$1<53N@)$$"@   !4P   *F 5, J8!I *F HKY5'X*_=
M2"/R+SDFN<\S?Q:?_P RL>G&J'@7>]/IETQ)%18D@BQ)%$DD$6)(HL20%B2"
M))(HL2018D@B22*56P@B22!58B%1))!%B2 MA%1;" DB!%J !$ M0!-!0,M!
M@CO9GZT\7WWVB&8:G6P,RV:; J%=8S -35 -3V-< H %3=  4,RU-?6!#N
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MA[>&"HYN]O#%$\W=WIB!S=[>& CF[V\,!/-WMX85%%H6W[])E73I 5%
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M@4340*@%.Z F@"* I2@( )KK ( " *@%0   0*)$  U@    "NL 5  4!
M $&9)2:E'1):3,P-3[%^K%V,E8837:3FJ)2_3D$K+T1XM,2(X1_\0I)ZCKI'
MWNNE/LCS\_-K^F-3UN2Y>G_I=&GHZO\ 67TF.J]4       !4_E4?@+]U((_
M)O."?ZQS)_%9_P#S*QZUNJ'SE_O3Z9=01#3"22!5;"*B22"+80%B2".1!ES;
M;+8N%MDNPKA%63L:7'6IIYIQ.DE(6DR,C(*5(F8TPY=YOU]S),*X9BN<J[3R
M0329$QU3RR;3J)3BT$6G6"+8C4MUUUTUF:N 1"LI(@$T%%J )H F@(FA )H
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M>BUWZ!(X [VW;C#S.'?NSV)\P\]>BUWZ!(X ;=N,+P[]V>Q'F'GKT6N_0)'
M#;MQ@X=^[/8>8>>O1:[] D\ -NW&$X=^[/8>8>>O1:[] D< -NW&%X=^[/8>
M8>>O1:[] D< -NW&#AW[L]AYAYY]%KOT"1P V[<8.'?NSV!9#SUZ+7?H$C@!
MMVXPG#OW9[#S#SUZ+7?H$C@!MVXPO#OW9[#S#SUZ+7?H$C@"[=N,'#OW9[#S
M#SUKY6N_0)' $V[<8.'?NSV'F'GKT6N_0)' #;MQ@X=^[/8>8>>O1:[] D<
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MHF@": )H!58B 21 )H DB!$T%$D0(DB 29: '+G_ *](_#,8<LZW'!
M( !4"H )H( !4 H :@* @ :@  :@*5! BJ"II0$0"@(   "O;_U9_P"Z;'\/
MF_%2.OS'N.UROS/4^RAY[UP  2 @   $@(  $@( =C9?UM7Y-7ND)+=FMWHC
MF    #T@    !:    2((%   0KY1'V?<$1(J@       !F          *J]
M^W["OM"(L*H FNB@"                45\LU^"O[0(N"@"2+14!
M      "=DA! HJKY5'X"_=2"/S(S5DB^NYKS Z@X>!RYS5IK+;(Z*D+/26L/
M8MU1Z'RE]]L7W:8URZHLBY@V873&QICB6XPL60\P[,+IC0'$MQA8LAYA_8NF
M-!4XEN,)+(68_P!BZ8T"<2W&%BR#F/\ 8NF- <2W&%O,#,G[%TQH#B68PDNS
M_,FQ#Z8T*<6W&%B[/\R[$+IC053BVXPL79]F7>PNF- <6W&$EV>YFWL/IC05
M.+;C"Q=GF9][#Z8T%3BV8PGZ/,SZR8?3&@JG%LQA)=G>:-[#Z8T%3BV8PL79
MWFG>0^F-!4XMN]"Q=G6:3^XA],:"IQ;,8279SFG>0^F-!5.+9C"Q=G&:N3A]
M,:"IQK-Z$EV;YKY.)TQH*G%LWH6+LVS7R</IC6Z%3BV8PGZ-LV<E$Z8UNBU3
MBV8PL79KFSDHG3&MT*G%LWH279IFWDHG3&MT*G%LQA8NS3-Q_P#\43IC053B
MV;T)^C+-QE\C$Z8SNA4XMF]"+AD7,)3Y)&4,C)PR,CEM5J0Q5SSFV8PXWF-F
M#]CZ6T%4XMF,'F-F#]CZ6T%3B68P>8V8=B'TMH*G%LQ@\QLP[$/I;05.+9C!
MYC9@_8^EM!4XMF,'F-F#]CZ6T%3BV8P>8V8?V/I;05.+9C!YC9@_8^EM!4XM
MF,'F-F#]CZ6T%3BV8P>8V8?V/I;6Z%3BV8P>8V8/V/I;05.+9C!YC9@_8^EM
M!4XMF,'F-F'9A]+:"IQ;,8/,;,/['TMH*G%LQ@\QLP_L?2V@J<6S&#S&S#^Q
M]+:W0J<6S&#S&S!^Q]+:"IQ;,8/,;,'['TMH*G%LQ@\QLP?L?2V@J<6S&#S&
MS#^Q]+:"IQ;,8/,;,/['TMH*G%LQ@/(V8?V/I;05.+9C!YC9A_8^EM!5>+9C
M!YC9@_8^EM!5.+9C!YBY@_8^EM!4XEF,'F-F#]CZ6T%3B68P>8V8?V/I;05.
M+9C#VQ]7+*-[A=IS#[Q1E-E F),FI"'%:4IUBTCKY\_H=WD[K;LVD3T2^O.J
M)^\3X1#SZO<V9.J)^\3X1!4V9.J)_)I\,@JFS)U1/WB?#2%5V9"M$_>)\,@J
M;,G5$_>)\(@J;,G5$_>)\(@J;,G5$_>)\(@J;,G5$_>)\,@J;,G5$_>)\-(5
M-F3JB?R:?#2%39DZHG[Q/A$%39ES+9 EQI!N.MF:<!EWADHZG36(2K5MLP[7
M"YR+G@B.0PN<BYX(!A<Y%SP0#"YR+G@@&%SD'/! ,+G(.>" 87.1<\$ PN<B
MYX(!A<Y%SP0#"YR+G@@&%SD7/! ,+G(N>" 87.1<\$ PN<BYX(!A<Y%SP0%3
M2YC1^)<U_N0%L+G(N>" 87.1<\$ PN<BYX(!A<Y!SP0#"YR+G@@&%SD7/! ,
M+G(.>" 87.1<\$ PN<@YX(!A<Y%SP0#"YR+G@@&%SD7/! ,+G(N>" $ESD7/
M! ,+G(N>" J:7.,1^*<U%?<^P"+87.1<\$%,+G(N>" 87.1<\$ PN<BYX(!A
M<Y%SP0#"YR+G@@&%SD7/! ,+G(.>" 87.1<\$ PN<BYX(!A<Y%SP0#"YR+G@
M@&%SD7/! ,+G(N>" 87.1<\$!FHG./:_%.:B]&'V 1IA<Y%SP04PN<BYX(!1
MWD7*?@@&%SD7/! ,+G(N>" 87.0<\$ PN<BYX(!A<Y%SP0#"YR+G@@&%SD7/
M! ,+G(N>" 87.1<\$ PN<BYX(!A<Y%SP0#"YR+G@@**2YQR/Q3GO%Z,/=2"/
M@',9?U+>_P"(2_SRA[EONQZ'PF;\R[]T_FZ\B&G$T)("Y)$1<B%%R($7(@1<
MD@+DD!<B!&A) 7(@1<B!%R2 ND@%R2"+DD$7(@&A%L +I2"-"(!H1 BY$"+D
M0"Q$"/&;KHNDW\LOW1QNW.MQ!4 4  0!0$  % 0 0 D     !0 ! ! "0  !
M0 !  !7M#ZOW]QV?W&7\5(Z_,>X]3[7\_P!4OJ@>:^N              !R(
M?RWV#$E8<XM014@                 #-7RC7V?< :$
M   #%?ZPS["_M -@                   <=W];C_@N?Y01R 4
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M;,5AZ/(?=./?-E\1;/1IU_ZO;3GZW'_!<_RCJO<<@%
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M%J24^+ .VVZVPG5FW4U$3G'$268J452I?OE'JG4+XBW1U=,S^*G+W7YDS?\
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M^^/     5(  @$     4  0  4  0    !0$      %2 @$ 4!    4U00
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M@$  % 0  4,$2"H! % 0        !0$          !(*@ !  !0$   [@
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M%$@   ]4?6&_\"B_Q2/\1P=CE_>]3P_O7R/^T/F8=]\>   "@(        5
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M#8 J  %2 *D 5( J0!4  *D 5(  *@%2  '&<_6V/P7/\H(Y-2!2I %2 *D
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M?3-V8>7T^(?X <&_ \TY;?CVGTS]F/E]/B'^ '!OP/-.5WX/IF[,/+Z?$/\
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M/?&%C4YYUNL(5D -4    P5 "00J0    "*@J=4$ #2 :H  :@" 4 20!4$
M    'LGL*_N"U^Y2OBI'!G^X]'[?\[U2^G1Y[Z-   D  0   "0$    ]<]M
MG_AS'\09^*L<^1[WJ>/]W^1_VAZ#'>?*                  "@(4!2A @
M H"   \DR-G*?D7,#-ZB5=BJHU<H=3(GXQG51?A)]\@]D8OLB^*.URO,W<OF
M;<:NF,8_TZ'V#:[I;[W;HUWM3Z9-NF()V.\G4-)ZQ[!D>@RUC'F3$Q-)??9>
M9;F6Q=;-8ERQ'(  "= @@4 %5?*(]A7VA$6%4 " 3J (        I74 #IK
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M32)MZH;G(C]4S.BVFJ*ZXPP>%D9'KU+9+4/NCE=)/L H" !H -    ((%2"
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MI8Z'M4M05D   !ZY[;/_  Z/_$&/BK'/D>]ZGC_=OD?]H>@QWGR@
M   * B05 (         H"    /<OU?LRWEB\R,IMQW)ECD(7+<4D^]@N)U7#
M,_N7/>FG5,])#J\Q;%*]+W_LV??%\Y<16V=/[?\ =]%D.D^M2>R @    !57
MRB/85]H$6!0     ]D      3LB"!0  $U 9K^7;]A?N$(BXJ@
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MWJ?:OG^J7U6/,?6@              WB_*_8,%AS2U!&@
M   9J(^,;.F@JUV@&@                   ,5_K#/L+^T V
M        !QW?UN/^"Y_E!'(!0                  8J_6FOR;GQD CXDOI
M?]>N_P"^R?SJA[MGNQZ'YSG?,N_=/YN&E-!IQ+DD!H1 BY$"+D0"Y$ N20&A
M$"M$I$5H21%:$D!JE(--4)$5JE(BM$I$::DD1IHE(*T)(BM4I$5H21&J-$I!
M6A)$::I2(JY)!7I[.O\ Y7=?RQ?%(<F7[L./F/F2Z(<CK@*   " "  !(
M  "@(  *  ( ( 2   *   " #VA]7W^X[7[C+^*D=?F/<>K]J^?ZI?58\Q]:
M              #UIVZ7B[6/)<:;99SUOF*N+#2GXR\"S;4A9FFI:QT'8R(B
M;M+Q_NV9?EY%;)FV=J-3Y[^D//\ Z3W'QZAW>';@^6\9G[]Q](>?_2>Y>/4'
M#MP/&9^_<?2'G_TGN7CU!P[<(/&9^_<?2'G[TGN7CU!P[<#QF?OW'TAY_P#2
M>Y>/4'#MP/&9^_<?2'G_ -)[EX]0<.W \9G[]Q](>?\ TGN7CU!P[<#QF?OW
M'TAY_P#2>Y>/4'#MP/&9^_<?2'G_ -)[ETA0<.W \9G[]Q](>?O2>Y>/4'#M
MP@\9G[]Q](>?O2>Y>/4'#MPA?&9^_<?2'G[TGN7CU!P[<(/&9^_<?2'G[TGN
M7CU!P[<(3QF?OW'TAY_])[EX]0<.W \9G[]Q](>?O2>Y>/4'#MP7QF?OW!]H
M6?M7SFN-?WA0<.W!/&9^_<?2'G[TGN7CU!P[<#QF?OW'TAY^])[EX]0<.W"%
M\9G[]Q](>?O2>Y>/4'#MP/&9^_<?2'G_ -)[ET@PX=N">,S]^X^D//\ Z3W+
MQZ@X=N$+XS/W[CZ0\_\ I/<ND*#AVX)XS/W[D_2'G[TGN7CU!P[<#QF?OW/8
MG9#VOW6'?2L.<+B[.MMU6E$6=*62E19!Z"(U'3\6ONZBAP9V3$Q6.AZOVW[C
M?;F;&;=6+M4ST3W3^;Z<05".NK4=!]>L       #%?ZPS["_M -@
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MZ@"        H   (   "@(]H_5]_N0S^XR_BI'7YCW'J_:_G^J7U4/,?6@
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M"O2&=O\ RR[?EO\ *0YLOW8=?F?FRZ$<C@  $ 4!    $ ) 0 D% 0  5 (
M "0 % 0!0$ 4   ![0^K[_<=K]QE_%2.OS'N/4^U_/\ 5+ZK'F/K0
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M")!0$   !0$     5[1^K]_<=K]QE_%2.MS'N/5^U_/]4OJH>:^L
M      !M&*KAZ::#U 6'-+4$:2                  ,U&?&-E70=:@-"
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M &_KAPYNI]ICY!U     !("        =C9?UM7Y-7VA);LUN^IH]@1S&KJ$
M@                !"O?H^R(B3U04%          H       "JOE$>PK[0(
ML"IJ @   #6H     4       !17RS7L+]PA$:&*J                  !
M4_E4?@+]U((_*+-B?ZLOW\2F?GUC[K*C]%OHAS6:G5$D<\0VN21J(%R2-"Y)
M&J#0DC5!H21J(%R2-1 N21J@T)(M!H2!H:)0*-4H$&B4"#1*!!HE(@T)(@N2
M1!<D[(@M0!8B$%B2 N21!8B$%B2 \/O7_>)_Y=?NC-NH<$50   0% 0 4!
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MZ5#?9:F,<\B.+;4E+L;$I''(.FE&)*DXM2I&,Q=$UI.I*PX@TH  .4U;K@_
MD75F(ZY;(CC;,J:E!FRTZ_B-M"UEH)2\*L)'JT,9FZ(FE=,E7%&E=U:<GYMO
MT"3=;%8;A<[9",RF3(<9U]EHTIQF2U(29%1.D^X.*_.LLFEUT1,LS+I=30>@
MRT&7='*L2[BT95S#?X,^Y6B"J1 MA).:_B0VE*G*X4)QJ3C<41&9-HJJA&=*
M$.._-MLF(F=,I5ULJ+*@2GH,YE<:;&6IF1&>2:'6W4'12%I.ADHC*AD8W$Q,
M5C4L2O+M\^W\W.=%=C%+91+B\<@T<;'=,R0ZBNJA5#HHM&@(NB=21-7&%4
M4   $ 'N;ZKO]UV?X;.^(0\C[M_;^N'#FZGVF/D'42 @!U)YJRLG,*<HJOD
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MLJ1<T616#%^(N,)6AR+,0DC<:5LEIJA6NDR]@?"<SR]V1?-MWJZX<#RT=8
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MU-3KA*NL6H/2<D:D T @ ]S_ %7/[KL_PZ=\0AY'W;^W]<.'-U/M(A\@ZB0
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M-F_<<DS9D/D566VBT?CDF>+%K)K75'A?>+LOAQ$^]T=7^CBNUOM7W1\FP@4
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MV%?:!%@4                  %#^7:]A?N$(BXJ@          GV1 IMZX
M8"!0  %5'^.0?WB_=2"/RWS2G^JK]_$IGY]8_2,F/_.WT1^3GMU.L)(YJ--"
M2-T5=*14:I0*-$H$&A($&J4"#1*!$:$@15R2(+$D07(@%B2(+$D!8B$%R2(+
M$D!8DB"Y%0!)$(+DD!8DB"Y)$%B2 \!OO_?+E^\N>Z-6ZH'7B@        *
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MN9YO,SYC;Z,$><#J"        5/Y1'^+W"$1850 K0!-:ZH"
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M I4@0J0!4@"I %0'8V73,41:O%J/W ENS6[[">P,N8PJ/6,!)D>P C"8!A,
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M :X OALK=A/-><^K=[.Y8LP7SY\OP&N 'A<K=A/-N<^K=[.Y<K]??GR_ :X
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MC<\LTZ/<(>)39R(CJ'VR6G53B09E4JZ@X;[+K)I=$Q/6Y;+[;XK;,3#G##8
M      #%?R[7L+^T!+8                   ''<_6X_P""Y_E!'(!0
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MRX!$.1P *5  $F"(!0 ! P4 *@&J  % 0!34!$ZH" 4 *@  ") 14%  $3J
M/=7U5_[L,_PZ9[B1X/WW^V]</J?_ )K^[_ZS_!]MCX%^F@
M]&_6Q(C[+HAF5:7B/2OY%T>_]B_N9_;/\'S?_P!%_:3Z8?%6%.]+:'WK\NK)
MA3O2V@*R84[TMH%K)A3O2V@*R84[TMH$K*<*-Z6T!6484[TMH"LIP(WI;0%9
M1A3O2V@*R84[TMH"LIP(WI;0%91A1L%M 5DPIWI;0+63"G>EM 5DPIWI;0)6
M4X$[TMH"LF!.]+: K)A3O2V@*RC"G>EM 5DPIWI;0%9,*=Z6T!63"G>EM 5D
MPHV"V@*R]H]B':O)[+\T(5*<6K*=R4EJ\1BJI*"K1,E"2KW[>O3WR:EL#R?N
M7(QS.7H]Z-7<]_[/]SGE<VET_HNU][] (,V+<8;$^"\B1"DH2]'D-&2D.-K(
ME)4DRU2,C'YU=;-LTG7#]5MNBZ*QIB7(&6@      8K^79]A?V@&P
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M7.]&[33,0]=(022)):A%3[ ]9X.IH2025B3LBI1=*:]P%AH2?;!5TI HL2:
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MF>1MRLN+YOKM>[^F:3'IQQCH>(^R.\\A-01 *  "01!  *   0(:   T  *
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M\[/6%O-EH@PF<W6E^^Y>DVIUU:4-PWB9?C2D/F:B<3C0I+B.\54RU2%'N<$
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M.92/<MU=?6_5_L_VV.4RM/OW:^Y[>(J%0>,]T      &*_EV?87]H!L
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M!I! @$T 0"@"00 >ZOJK_P!V&OX=,]Q(\'[[_;>N'U/_ ,U_=_\ 6?X/ML?
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M)]T^[6YMO#RIT3KG^'>^B^S?9;LB_B9OO1JC^/<^FZ4'RS[$       !BO\
M6&?87]H!L                   #CN_K<?\%S_*".0"@
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MK1Z&S<5,U7HOVU_XYA9[L-9WO.F&W"
M    #W']6+^Z;7\/F?%2/%^\?V_KA[_V/^X]4OLL?&ON0!("    2 @  2 @
M  =C9OUM7Y-7VA);LUN]$<P   "1!%!0     ! ,4-("2$$"B#]^C[/N"(D]
M450            !.MW1!%0 4 %5?*(_Q>X0(L"@           )J9@(
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M<$%5>_1]GW 1)ZHJ@               )(@ 045\HC_%]H5%@4
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M*IKH,$F)AY2*@ ]*_6D_MI%_BT?\TZ/9^S_/]3Q?O/\ ;3Z8?'8^S? @
M   !'0%>Z/J\]L2NS?,'4MZ>IDF]NI*<:B,^:23+"B2FFFFHETM=.G6'C_<N
M2X]FU;[UOMZGO_:/N' OV+O<N]G6^]$F2B):32I"BQ(4D\25),JD9&6J1D/B
M7Z  H DMD!   A7OT?XA$2>J*H                  *GI<1_B^T"+&"@
MG6J((%        $Z-<!    **^6:_!7]H1%Q5                  !4_E4
M?@+^,D$?GI?T_P!27L__ +"7^>4/U3(^59^V/R?B^?\ /S/WW?FX)$.9Q56)
M(J+DD&5TIH N23,4:);$JM&J6QFK40U2@1:-4H$5JE BM4MB5:HU2V)5:-DH
M&:M4:I0)5JC5*!FK5&J4"56C5+8E6J-4H&5AJE 56C5*!EJC5*!%HU2@1J(:
MI0,U:HV0WI(2JT?-^<]&;[]^_2/CF.;+]V'%G^_+S2VW"VL9*FVK-&8+?>[
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M(SHA/W*:$/SW/S>+?-]*5?J.1E<++BRM:.]'"YP    !"OE$?XA$6J"H%
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M0R]D17S+G71G&_%L3Y'QS'/E>[#@YCWY=$.5UP
M            >X_JQ?W3:_A\SXJ1XOWC^W]</?\ L?\ <>J7V6/C7W*0$
M D!   D!    /2OUI/[:13_^VC_FG1[/V?Y_J>+]Y_MI],/CJI;(^S? E2V0
M"I;(!4MD J6R 5+9 *EL@+(2IQ:6VTFMQ9DE"$EB4I1G0B(BU3,Q)EJ(F9I#
M[T^KUV.M]G&72O=[CFG.]Z:2J:EPBQ0HQGB1&32M%'H4Z>SWNL/B/N7.\>_9
MM]R/;UOT7[7R$<MEUGW[M?<]SD>FH\E[0  %-%0   0?OT?XA$2>J*H
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MS=;:@^<(C2*F@G4:$JT&6DB,QO+S;\N:V326;LFS-C9OBL.+]"'8_P"AEO\
M!7PAV/'<QORXO+N6^G:?0AV/^AMO\%?"#QW,;\GEW+?3M/H0['_0RW^"OA!X
M[F-^3R[EOIVGT(=C_H9;_!7P@\?S&_)Y=RWT[3Z$.Q_T,M_@KX0>.YC?D\NY
M;Z=I]"'8_P"AEO\ !7P@\?S&_)Y=RWT[3Z$.Q_T,M_@KX0>/YC?D\NY;Z=KD
MV_L@[+;3.CW2VY2M\>X1'$O17R0I1MN(TI41*495(]):!F[G,^Z*3?-):LY'
ME[)K;9$3#S0]6IZ3/29F.H[Q0!(@@4*ZP  ""%>_1]GW 18P4/10! H
M           JKW[?^+[0B+"JDP$5     3J]SNB"!0   ]4 KK     **^6;
M]A?V@1>H*                  "ID?'(+[Q?NI!'PC?;!<U7^\+0J":5SI2
MBK<H"3H;JCTD;]2/N&/U'(SK.%9K]V/^-V'H?C?,\OF\;,IL^]=_SLQ_<X:<
MOW/9@_S.W_IQR\:SK^&[N<'A\W"W_P#2S^IJFP7/9@_S.W_IQGC6=?PW=S7
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M$!0YL[LM^-;X0%#FSNRWXUOA 4.;.[+?C6^$!0YL[LM^-;X0%#FSNRWXUOA
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L+=$ T'W.[I+= ,!]S;+=%# ?<VRW0# KN;9;H"IH5QJ-3WB_NBV4]T$?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
